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Genetics of cancer
Cancer is generally considered to be a disease of the genome. It all started in 1914, 
when cytologist Boveri proposed the idea that cancer results from a deranged genome 
and that chromosomal defects might cause a cell to proliferate abnormally (Boveri, 
1914, 2008). Though this hypothesis seems self-evident now, during the ensuing years 
intense interest accumulated around the notion that cancer was primarily caused 
by viruses. Indeed, viral etiology seemed to be a prominent premise when Nobel 
laureates Bishop and Varmus set out to study the src sequences present within the 
Rous Sarcoma Virus genome that transferred malignant properties to normal avian 
cells (Stehelin et al., 1976). By querying oncogenic src sequences, however, Bishop 
and Varmus made the unexpected observation that these sequences were already 
present in the normal avian genome, even in uninfected chicken cells (Stehelin et 
al., 1976). This discovery gave birth to the idea that cancer might arise from altered 
functions of normal cellular genes. The definite evidence for human oncogenes as 
mutated versions of normal cellular genes came from studies of the HRAS gene 
in bladder cancer (Parada et al., 1982). The finding of a single nucleotide change 
at codon 12, which provided the basis for HRAS oncogenicity, firmly established 
the genomic basis of cancer (Tabin et al., 1982). In the years that followed several 
genomic alterations that give rise to cancer were elaborated. The RAS oncogene 
family (HRAS, KRAS and NRAS) became the exemplar of nucleotide substitutions 
(or base mutations) that generate somatically altered proteins. Additional categories 
of genomic alterations were discovered by the longstanding recognition that cancers 
frequently harbor chromosomal rearrangements. The Philadelphia chromosome, 
which is invariably present in chronic myelogenous leukemia cells (Nowell and 
Hungerford, 1960), was the first consistent chromosomal abnormality described in 
any malignancy. It was later found that the Philadelphia chromosome consists of a 
translocation between the long arms of chromosome 9 and 22 (Rowley, 1973). The 
ABL1 gene, previously denoted as a viral oncogene, was identified as a critical gene 
activated by the t(9;22) translocation (de Klein et al., 1982). Thus, chromosomal 
translocations (or DNA rearrangements) became also recognized as a major class 
of genomic events. In 1982, the MYC gene was identified as the cellular homolog 
of another viral oncogene (Vennstrom et al., 1982) and was shown to be targeted 
by a chromosomal translocation in Burkitt’s lymphomas (Taub et al., 1982). The 
identification of high-level amplification of the MYC gene in several cancer types 
(Collins and Groudine, 1982, Alitalo et al., 1983, Little et al., 1983, Nowell et al., 
1983, Schwab et al., 1983) acknowledged genomic amplifications and copy gains as 
additional cardinal mechanisms involved in cancer gene deregulation. Subsequent 
studies on hereditary retinoblastoma led to the discovery of the first tumor suppressor 
gene, RB1 (Friend et al, 1986). The two-hit hypothesis of tumor suppressor genes 
originated from an observation by Knudson (Knudson, 1971) that the onset of 
retinoblastoma follows second-order kinetics, implying that two independent genetic 
events were necessary. According to this two-hit hypothesis, the first event is a point 
mutation that inactivates one copy of a tumor suppressor gene, whereas the second 
hit involves a mutation or deletion within the other chromosome that inactivates or 
eliminates the remaining wild-type allele. Tumor suppressor genes, such as CDKN2A 
and PTEN, are commonly affected by homozygous deletions. Consequently,
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chromosomal deletions resulting in complete or partial genomic losses constitute 
another prominent mechanism contributing to tumor initiation and/or progression.
Genetics of colorectal cancer
Colorectal tumorigenesis represents a multistep process involving various molecular 
events that underlie its initiation and progression (Figure 1) (Foulds 1958, Vogelstein 
et al., 1988, Weinberg 1989, Vogelstein and Kinzler, 1993, Attolini et al., 2010). 
Colorectal cancer provides a useful model for other cancers since the various stages 
of tumor development can be observed and obtained for study with relative ease, 
unlike the situation in most other common human tumor types. The sequence of 
events from aberrant crypt proliferation or hyperplasia to benign adenomas, then to 
carcinoma in situ and finally to metastatic carcinomas are very well defined, and often 
occurs over many years. Early genetic alterations in the genesis of colorectal tumors 
almost invariably include mutations in the tumor suppressor gene APC (Powell, 1992). 
The tumor morphology and the likelihood of tumor progression is predominantly 
dependent on the temporal order rather than the accumulation of genetic changes. 
In the earliest stages of the adenoma-carcinoma sequence, known as aberrant crypt 
foci (ACF), mutations in APC are associated with the degree of dysplasia of these 
small lesions (Jen et al., 1994, Smith et al., 1994). In chromosome 5q21, where 
APC is located, both point mutations and allelic losses have been found (Solomon 
et al., 1987, Okamoto et al., 1988, Powell et al., 1992). An additional oncogenic 
KRAS mutation is required for adenoma growth and progression (Vogelstein et al., 
1988). It is apparent that the synergistic action of the mutated APC and KRAS genes 
underlies clonal expansion and dysplasia in the nascent colorectal tumor (Fodde et 
al., 2001). KRAS mutations are also found in nondysplastic ACF and hyperplastic 
polpys that have a more limited potential to progress to larger tumors (Vogelstein 
et al., 1988). Subsequent clonal expansion and malignant transformation is driven 
by additional mutations and allelic losses, presumably centered around the tumor 
suppressor genes SMAD4 and TP53. 17p losses are found in 75% of colorectal 
carcinomas, but infrequently in benign lesions, which indicates that loss of p53 
function is involved in late progression rather than initiation (Vogelstein et al., 1988, 
Rodrigues et al., 1990). Allelic loss of chromosome 17p is almost always associated 
with missense mutations in the remaining TP53 allele, in line with Knudson’s two-hit 
model for tumor suppressor genes (Baker et al., 1989). It has been predicted that 
at least seven genetic hits are required for full-blown colorectal cancer development 
(Fodde et al., 2001). Indeed, genomic profiling efforts have yielded a handful of 
commonly mutated genes and a larger number of infrequently mutated genes (Wood 
et al., 2007).
Epigenetics of cancer
Increasing evidence indicates that also aberrant epigenetic gene regulation 
may serve as a common mechanism underlying cancer development. In recent 
years, considerable progress has been made in the identification and detailed 












Figure 1. Genetic model for colorectal tumorigenesis. Colorectal carcinomas arise 
as result of a series of genetic alterations involving a handful of oncogenes and tumor 
suppressor genes. The earliest stages of the adenoma-carcinoma sequence is the 
aberrant crypt focus (ACF), which is associated with loss of the APC tumor suppressor 
gene function. Intermediate/late adenomas and early carcinomas are associated with the 
acquisition of mutations in the KRAS oncogene, followed by losses of or mutations in the 
SMAD4 and TP53 tumor suppressor genes. (Adapted from: Fodde et al., 2001).
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in cancer (Esteller, 2008, Muntean and Hess, 2009). Such regulation may be subject 
to three different, but highly interdependent, mechanisms: (i) histone modification, 
(ii) DNA (de-)methylation, and (iii) chromatin remodeling. The basic chromatin unit, 
the nucleosome, consists of two of the four different core histone proteins with 
DNA wound around it. These histone proteins can undergo reversible covalent 
modifications (Figure. 2), which alter their interaction with DNA and other nuclear 
proteins. These modifications occur on specific amino acid residues, notably lysine 
and arginine (Cosgrove et al., 2004). Histone modifications, including methylation 
and acetylation, play an important role in chromatin packaging and concomitant 
gene expression. Overall, histone hypoacetylation and hypermethylation are 
characteristics of chromatin regions that are transcriptionally repressed (LaVoie,
2005). Histone methylation generally leads to chromatin compaction. Detailed 
elucidation of sites of histone methylation, however, has revealed that some 
methylation events may also confer transcriptional activation. Histone acetylation 
is catalysed by histone acetylases (HATs) and has been associated with increased 
nucleosome mobility and the promotion of gene expression (Cosgrove et al., 
2004). Histone acetylation induces relaxation of condensed chromatin (Toth et al.,
2006). This reduces the binding affinity between histones and DNA and, by doing 
so, renders the DNA better accessible for transcription. The converse process of 
histone de-acetylation is catalysed by histone de-acetylases (HDACs), which are 
associated with DNA methyltransferases (DNMT) through direct protein-protein 
interactions (Fuks et al., 2001, Deplus et al., 2002). DNA methylation of cytosine 
residues in CpG di-nucleotides, often clustered in so-called CpG islands, leads to 
transcriptional silencing of the associated genes. This silencing may be achieved 
by the multiprotein repression complex NuRD, which is targeted to methylated DNA 
by methyl-DNA binding proteins (Zhang et al., 1999, Harikrishnan et al., 2005). The 
covalent chromatin modifications mentioned above affect epigenetic gene regulation 
at a different level than chromatin remodeling, i.e., chromatin remodeling involves a 
repositioning of the DNA around histones, thereby allowing DNA binding proteins to 
gain access to the DNA (Kwon et al., 1994, Johnson et al., 2005). This process does 
not involve chemical alterations of histones, but is an energy (ATPase)-dependent 
process that determines contacts between histones and DNA (Johnson et al., 2005). 
The proteins responsible for chromatin remodeling act together in large complexes 
(Cairns, 2005).
Noncoding RNAs
Gene regulation by noncoding RNAs is considered a specific form of epigenetic 
regulation. MiRNAs are noncoding RNAs of ~22 nucleotides (nt) in length that regulate 
gene expression by sequence-specific base pairing in the 3’ or 5’ untranslated regions 
of target mRNAs. This results in mRNA degradation or inhibition of translation. 
Normally, the expression of miRNAs is tightly regulated and plays an important 
role in cell differentiation, proliferation and apoptosis (He and Hannon, 2004). 
MiRNA expression is deregulated in cancer by a variety of mechanisms including 
amplification, deletion and mutation (Garzon et al., 2009). Until now, abnormal 
expression of several miRNAs has been implicated in the etiology, progression,
16
Figure 2. Epigenetic marks, including DNA cytosine methylation (Me) and covalent 
histone acetylation (Ac) or methylation (Me), that affect transcription. (Adapted from: 
Jones et al., 2008).
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and prognosis of cancer, and their expression profiles are uniquely linked to various 
cancer types and subtypes. Well-known examples include the miRNA cluster 17-92 
located at 13q31, a region commonly amplified in lymphomas (Ota et al., 2004), 
miR-143 and miR-145 located at 5q33 and frequently deleted in myelodysplastic 
syndromes (Calin et al., 2004) and a rearrangement of miR-125b-1, juxtaposed to 
the immunoglobulin heavy chain locus, in B-cell acute lymphocytic leukemia (Sonoki 
et al., 2005). The gain or loss of specific miRNAs implies both oncogene and tumor 
suppressor gene functions, the archetypical examples of which are miR-21 and Let-7, 
respectively (Chen, 2005, Ryan et al., 2010). Also, hypermethylation of 5’ regulatory 
regions has been observed as a mechanism for the downregulation of miRNAs in 
tumors (Lujambio et al., 2007). Furthermore, SNPs or point mutations in miRNAs 
may confer cancer susceptibility, as first reported for miR-16-1 in a kindred with 
familial chronic lymphocytic leukemia (Calin et al., 2005). It can be presumed that, 
as the miRNAome evolves, new candidate SNPs and forms of genetic variation may 
be linked to cancer development and its susceptibility (Geurts van Kessel, 2010).
Epigenetics of colorectal cancer
It was first recognized more than 25 years ago that in colorectal cancer cells global 
DNA methylation patterns differed considerably from those in their normal counterparts 
(Feinberg and Vogelstein, 1983). Since then, various reports have confirmed this 
initial finding and have associated hypermethylation of tumor suppressor genes and 
hypomethylation of oncogenes to tumorigenic processes (Esteller 2008, Gargiulo 
and Minucci, 2009). Hypomethylation phenomena may convey diverse effects upon 
living (epithelial) cells, including an increase in genome instability, over-expression 
of a variety of genes and loss of imprinting of particular genes such as IGF2, 
the latter of which has indeed been implicated in the pathogenesis of colorectal 
cancer (Cui et al., 2003). Next to global hypomethylation discrete hypermethylation, 
targeting promoter regions of specific genes, has also frequently been observed 
in various cancer types, including colorectal cancer (Esteller, 2008). Many of the 
genes affected by hypermethylation are involved in cell cycle regulation, DNA repair, 
apoptosis, angiogenesis, invasion and adhesion. Promoter hypermethylation of the 
MLH1, APC, RB1, VHL, MGMT, GSTP1 and BRCA1 genes, represent paradigmatic 
cancer-related epigenetic silencing events (Esteller, 2000, Feinberg and Tycko,
2004). Interestingly, it was found that sporadic and inherited cancers may exhibit 
similar DNA methylation patterns (Esteller et al., 2001) and many genes that are 
mutated in familial cancers have also been found to be hypermethylated, mutated or 
deleted in sporadic cancers. The DNA mismatch repair gene MLH1, for example, can 
be inactivated by hypermethylation or mutation in both inherited and non-inherited 
colorectal cancers (Cui et al., 1998, Esteller et al., 2001).
There are at least two molecular pathways leading to sporadic colorectal cancer 
development, i.e., the chromosomal instability (CIN) pathway and the CpG island 
methylator phenotype (CIMP) pathway (Shen et al., 2007, Grady and Carethers, 
Issa 2008). CIN tumors account for approximately 80% of colorectal cancers in 
which genetic instability drives the adenoma-carcinoma sequence (Vogelstein et al., 
1988). Tumors that develop through this pathway are frequently located at the distal
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site of the colon, exhibit a microsatellite stable but aneuploid phenotype and arise 
from colorectal adenomas. Although the exact mechanism that underlies aberrant 
DNA methylation in CIMP tumors still remains to be elucidated, current evidence 
suggests that it may be an early, possibly tumor initiating, event. In contrast to CIN 
tumors, CIMP tumors show less severe aneuploidy. BRAF, or occasionally KRAS, 
mutation-induced activation of the RAS-RAF-MEK-ERK pathway is another important 
characteristic of CIMP tumors (Jass et al., 2002, Kambara et al., 2004, Weisenberger 
et al., 2006, Shen et al., 2007). In contrast to the CIN tumors, CIMP tumors frequently 
develop within the proximal colon, arise from serrated rather than adenomatous 
polyps, are microsatellite instable, occur more common in elderly females than in 
males and are associated with distinct survival and treatment outcomes (Jass et al., 
2007, Muntean and Hess, 2009, Ogino et al., 2009). Previously, two CIMP subgroups 
were discerned, i.e., CIMP-1 and CIMP-2, that displayed increased frequencies of 
BRAF and KRAS mutations, respectively. The recent assessment of 1,505 CpG 
islands within 807 cancer-related genes in 91 unselected colorectal cancers allowed 
a further distinction of three subgroups according to their methylation pattern. These 
subgroups showed different clinico-pathological and molecular features and, again, 
differed in their frequencies of BRAF and KRAS mutations (Ang et al., 2010). The 
genes methylated in colorectal cancer can be characterized as type A (age related) or 
type C (cancer related) (Toyota et al., 1999). Generally, type A genes are methylated 
in both normal and neoplastic tissues. Hypermethylation of these genes may not 
be directly implicated in colorectal cancer development. The methylation of type C 
genes, however, is more specific to neoplastic tissues. Methylation of certain type C 
genes defines CIMP tumors, whereas that of other genes may be less discriminatory 
for CIMP or CIN tumors. Recently, it was shown that DNA methylation patterns within 
normal mucosa varied with age and region and, as such, might be associated with 
CIMP or CIN pathway-specific predispositions to colorectal cancer development 
(Worthley et al., 2010).
Colorectal cancer-associated syndromes
The frequency of familial colorectal cancers depends on the definition used, but 
is usually estimated between 20 and 30% (de la Chapelle, 2004). Approximately 
10% of colorectal cancer patients have a first degree affected relative (Michils et al.,
2005). Up till now, several colorectal cancer syndromes with Mendelian dominant 
inheritance patterns have been identified and they can be subdivided into two major 
groups presenting with non-polyposis or polyposis, respectively. Lynch syndrome 
(also known as hereditary non-polyposis colorectal cancer, HNPCC) represents 
the major non-polyposis colorectal cancer syndrome and is caused by defects in 
DNA mismatch repair (MMR) genes, i.e., the MLH1, MSH2, PMS2 or MSH6 genes. 
Carriers of mutations in either one of these genes have a high risk to develop 
colorectal cancer (60-90%) and/or endometrial cancer (20-60%) and, to a lesser 
extent, cancer of the small bowel, stomach, ovary, urinary tract and/or hepatobiliary 
tract (Lynch and de la Chapelle, 2003, van der Post et al., 2010). Somatic second 
hit mutations of the wild-type allele in the tumors leads to MMR deficiency, resulting 
in genetic instability and increased DNA mutation rates. Microsatellite instability
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(MSI), represented by insertions and/or deletions in short repeated DNA sequences, 
is the most extreme manifestation of this increased mutation rate and provides an 
excellent diagnostic marker for MMR deficiency (Aaltonen et al., 1994, Boland et al., 
1998). It has been shown that in 78% of the families suspected of Lynch syndrome 
with an MSI-positive tumour and absence of hypermethylation of the MLH1 promoter 
(see below) a disease-causing germline mutation in one of the MMR genes can 
be identified (Overbeek et al., 2007). Subtypes of Lynch syndrome include Muir- 
Torre syndrome, which is characterized by the presence of sebaceous tumors mainly 
caused by MSH2 mutations (Kruse et al., 1998) and Turcot syndrome, which is 
associated with the occurrence of central nervous system tumors (Hamilton et al., 
1995, de Vos et al., 2004).
A well-defined hereditary form of polyposis colorectal cancer is caused by germline 
mutations in the APC gene. Most carriers of such mutations will inevitably develop 
familial adenomatous polyposis (FAP), which is characterized by the appearance 
of hundreds to thousands of adenomatous polyps in the colon during the second 
and third decades of their life, followed by colorectal cancer at the age of 40-50 
years. The polyps arise from colorectal epithelial stem cells that have acquired an 
additional rate-limiting somatic mutation in the wild-type APC allele. Once the role of 
APC in FAP was established, mutations in this gene appeared to be one of the most 
frequent early events in sporadic colorectal cancers as well (~80% of the cases, 
see above; Kinzler and Vogelstein, 1996). APC inactivating mutations usually result 
in truncation of the protein which, in turn, results in interference with its binding to 
G-catenin. APC binding to G-catenin is an essential step in the repression of the 
Wnt signalling cascade and, thereby, the regulation of growth and differentiation 
in the colorectal epithelial stem cell compartment (Fodde and Brabletz, 2007). In 
addition to Wnt signalling, G-catenin links APC to cellular adhesion and migration, 
and several studies have shown that G-catenin is necessary for cadherin-mediated 
cell adhesion. Based on these data, it has been proposed that APC mutations 
contribute to tumorigenesis by altering the relative adhesiveness of colonic epithelial 
cells and misregulating the integrity of cadherin-catenin complexes (Goss and 
Groden, 2000). In addition to FAP, an attenuated form (AFAP) of colorectal cancer 
exists which exhibits fewer polyps, and which is associated with mutations at the 
extreme 5’ and 3’ ends of the APC gene (Spirio et al., 1993). Other less frequent 
polyposis-associated colorectal cancer syndromes have also been described and 
include Gardner syndrome, which has been diagnosed in patients with extra-colonic 
features of FAP, i.e., jaw cysts, osteomata, pigmented retinal lesions and desmoids 
tumors. By now, there is consensus that this latter syndrome is synonymous to FAP 
(Galiatsatos and Foulkes, 2006). Furthermore, Turcot syndrome is characterized by 
adenomatous polyposis together with early-onset central nervous system tumors 
and is caused by either APC gene mutations or (bi-allelic) mismatch repair gene 
mutations (see above, Hamilton et al., 1995, de Vos et al., 2004). In contrast to the 
above mentioned syndromes, the MUTYH-associated polyposis (MAP) syndrome 
exhibits an autosomal recessive inheritance pattern and results from bi-allelic 
mutations in the MUTYH gene, the human orthologue of the Escherichia coli excision 
repair gene mutY. These mutations were first detected in a single family with three 
affected and four unaffected siblings (Al-Tassan et al., 2002). Whereas monoallelic
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MUTYH carriers failed to show an increased risk for colorectal cancer, the overall 
contribution of MUTYH mutations to colorectal cancer turned out to be substantial 
(Balaguer et al., 2007). This latter finding indicates that recessive colorectal cancer 
predisposing mutations may be more common than previously thought. Germline 
mutations in the LKB1/STK11 gene have been shown to cause Peutz-Jehgers 
syndrome (PJS) (Hemminki et al., 1998, Jenne et al., 1998), and mutations in 
the SMAD4 and BMPR1A genes have been shown to underlie juvenile polyposis 
syndrome (JPS) (Houlston et al., 1998, Howe et al., 1998, 2001). Tumors from the 
latter syndrome show a histologically distinct, hamartomatous, phenotype.
Figure 3. Colorectal cancer (CRC) incidence. CRCs can be divided into sporadic, familial 
and hereditary cases. In total, 35% of the CRCs are assumed to result from a genetic 
defect but, as yet, only ~5% of them has been associated with a high-penetrant dominant 
or recessive inherited syndrome, such as Lynch syndrome. In 20-30% of the familial and 
de novo early-onset CRC patients (usually classified as sporadic; black dots), the genetic 
defect remains to be resolved. This sub-group has been the focus of our study to identify 
novel CRC susceptibility genes. (Adapted from: Lynch et al., 2004).
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Missing heritability in cancer
Together, the above mentioned syndromes are responsible for ~5% of all colorectal 
cancers, whereas twin studies have suggested that another 20 and 30% of 
colorectal cancers may be ascribed to genetic susceptibility (Figure 3) (Lichtenstein 
et al., 2000, Lynch and de la Chapelle, 2003, de la Chapelle, 2004). A majority of 
this risk is attributed to low susceptibility to moderate susceptibility genetic variants 
according to two alternative hypotheses: the “Common disease, common variant” 
(CDCV) versus “Common disease, rare variant” (CDRV) hypothesis (Bodmer and 
Bonilla, 2008). The CDCV hypothesis states that multiple common variants (>5%), 
each attributing to only a minor increase in susceptibility, substantially influence 
the risk for a common disease. Recent developments in genotyping technologies 
have enabled the identification of such genetic variants in a more or less unbiased 
manner by analyzing thousands of affected individuals and controls for thousands 
of single nucleotide polymorphisms (SNPs) covering the entire human genome. It 
has to be noted that in copy number variable regions and in duplicated regions of 
the genome, the analysis of high-throughput SNP typing data still remains to be 
difficult (Fredman et al., 2004). Genome-wide association (GWA) studies performed 
in several cancers (including breast, prostate, colorectal, and lung) have resulted 
in a wealth of genotyping data from various ethnic populations and hundreds of 
SNPs that are significantly associated with an increased cancer risk, thereby clearly 
demonstrating that the CDCV model is valid. Fourteen different loci, including those 
which appear to be associated with TGF-p signaling, have so far been identified in 
colorectal cancer (Tenesa and Dunlop, 2009, Tomlinson et al., 2010, Houlston et 
al., 2010). Two studies have shown that a common variant on chromosome 8q24 
affects Wnt signaling and MYC expression (Tuupanen et al., 2009, Pomerantz et 
al., 2009). In addition, it has been shown that allelic variation at a common variant 
on chromosome 8q23.3 acts as a c/s-acting regulator of the eukaryotic translation 
initiation factor 3 subunit H gene EIF3H whose increased expression results in 
colorectal cancer growth and invasiveness (Pittman et al., 2010). These studies 
provide the first functional indications on how these common variants can influence 
cancer risk. So far, however, these common variants still may explain only a small 
percentage of the heritability of cancer.
According to CDRV model at least part of the missing heritability could be explained 
by a cumulative effect of multiple rare variants. These variants, occurring with 
frequencies <1%, act as independent dominant susceptibility factors each conveying 
a moderate but significant increase in cancer risk (Bodmer and Bonilla, 2008). 
Such rare variants could be identified by hypothesis-driven strategies based on 
the assumption that they affect genes involved in, for instance, Wnt signaling or 
mismatch repair in colorectal cancer (Frayling et al., 1998, Lipkin et al., Fearnhead 
et al., 2004), and double strand break repair in breast cancer (Meijers-Heijboer et 
al., 2002, Seal et al., 2006, Rahman et al., 2007). Such rare variants, however, will 
not be detected by even very extensive GWA studies because of their low frequency 
and individually limited contributions to the overall risk to disease development, thus 
indicating that alternative strategies are required for their identification.
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Copy number variation and cancer susceptibility
Although most high-penetrant genes are frequently affected by point mutations, 
there are many reports of gross genomic rearrangements that may underlie cancer 
susceptibility. Examples of these are constitutional chromosome translocations in 
families susceptible to e.g. Wilms’ tumor (Sossey-Alaoui et al., 2002), hematological 
malignancy (Hill et al., 2003), ganglioneuroblastoma (Vernon et al., 2003), renal 
cell carcinoma (Bonné et al., 2004), bladder cancer (Guo et al., 2004), germ 
cell cancer (Veltman et al., 2005) and breast cancer (Wieland et al., 2006). In 
addition, constitutional copy number variants (CNVs), usually micro-deletions, 
have frequently been encountered in cancer-prone families and were shown to be 
of critical importance for the identification of novel predisposing genes (Kuiper et 
al., 2010), such as the RB1 gene on 13q14 implicated in retinoblastoma (Francke 
and Kung, 1976, Friend et al, 1986), the WT1 gene on 11p13 implicated in Wilms’ 
tumor (Riccardi et al., 1978, Call et al., 1990), the APC gene on 5q21 implicated in 
familial adenomatous polyposis (Herrera et al., 1986), the mismatch repair genes 
in Lynch syndrome (Nystrom-Lahti et al., 1995, Wijnen et al., 1998, Plaschke et al., 
2003, van der Klift et al., 2005, Overbeek et al., 2007), the VHL gene implicated 
in the von Hippel Lindau cancer syndrome (Latif et al., 1993), the PTEN gene on 
10q23 implicated in Cowden syndrome (Tsuchiya et al., 1998) and the NF1 gene on 
17q11 implicated in type-1 neurofibromatosis (Lopez-Correa et al., 1999). All these 
genes were also found to be affected in various non-hereditary forms of cancer, 
thus illustrating their role in tumor development. Several studies have explored the 
frequency of copy number variation of well known high-penetrant cancer predisposing 
genes, including the MMR and APC genes, the BRCA1 and BRCA2 genes and the 
VHL gene. These studies revealed that such copy number variation may occur in 
about 4-15% of the families, which has turned DNA dosage analysis into an essential 
component of genetic screening for cancer predisposition (Petrij-Bosch et al., 1997, 
Wijnen et al., 1998, Wagner et al., 2003, Bunyan et al., 2004, Michils et al., 2005). 
Van der Klift et al. (2005) performed a systematic search for genomic variants in 
a cohort of 439 Lynch families and identified 48 rearrangements in 68 unrelated 
kindreds, of which six left the coding region of the disease gene intact. Interestingly, 
these rearrangements comprised four deletions upstream of the coding region of the 
MSH2 gene (see below).
Copy number variation and novel hereditary mechanisms
About one-third of all cases that meet Lynch syndrome criteria do not exhibit 
pathogenic mutations in either of the known MMR genes and, thus, their genetic 
origin awaits elucidation. In 2002 Gazzoli et al. identified a person with early- 
onset colorectal cancer who lacked MMR gene mutations but, instead, showed 
constitutional hemi-allelic methylation of the MLH1 gene. The tumor of this patient 
showed microsatellite instability and a complete loss of MLH1 expression due to 
somatic deletion of the second, unmethylated allele. The subsequent identification 
of similar familial cases allowed a further characterization of MLH1 germline 
epimutations. Methylation of CpG sites in the respective patients was shown to 
be restricted to a single allele by employing a SNP within the MLH1 promoter for
23
Chapter 1
which the patients were heterozygous (Miyakura et al., 2004, Suter et al., 2004, 
Hitchins et al., 2005, Hitchins et al., 2007). Transcriptional loss of the affected allele 
was also confirmed at the mRNA level in normal cells by exploiting SNPs located 
within coding regions (exons) of the MLH1 gene, for which the mutation carriers 
were heterozygous (Hitchins et al., 2005, Hitchins et al., 2007). Germline MLH1 
epimutations are likely to be associated with repressive histone modifications and/ 
or other epigenetic changes that accompany cytosine methylation (Hitchins and 
Ward, 2009). It was found that MLH1 epimutation carriers exhibited mono- or hemi- 
allelic MLH1 methylation patterns throughout their normal somatic tissues, including 
tissues derived from all three embryonic germ cell lineages, i.e., buccal- and colonic 
epithelium cells (endodermal), peripheral blood lymphocytes (mesodermal), and 
hair follicle cells (ectodermal) (Miyakura et al., 2004, Suter et al., 2004, Hitchins et 
al., 2005, Hitchins et al., 2007). These findings strongly suggest that the observed 
epimutations, or the mechanism(s) underlying them, must have arisen in the respective 
germlines (Suter et al., 2004). Germline MLH1 epimutations are distinct from somatic 
epigenetic MLH1 silencing events, which are observed in sporadic microsatellite 
instable colorectal cancers of the elderly, where bi-allelic methylation of MLH1 and 
its flanking genes is essentially confined to the tumors (Hitchins and Ward, 2009). It 
is thought that de novo methylation of the core promoter of this gene is seeded from 
flanking methylated sites, which may also explain the apparent stochastic process 
of de novo methylation events observed in these cancers (Clark and Melki, 2002). 
Additionally, the penetrance of germline MLH1 promoter methylation may not be 
complete, as was exemplified by a family in which a male Lynch syndrome proband 
was found to have inherited the epimutation from his unaffected mother (Morak et 
al., 2008). Through another interesting observation, Hitchins et al. (2007) were able 
to show that germline MLH1 epimutations may follow a non-Mendelian inheritance 
pattern and, in addition, may be reversible. Specifically, they found that a germline 
MLH1 epimutation was transmitted from a female patient to one of her sons, but 
was erased in two other sons who had also inherited the affected maternal allele 
(Hitchins et al., 2007). Together, these observations suggest that in different patients 
germline epimutations may be caused by different mechanisms associated with 
different inheritance and transmission patterns. Whereas the exact nature of the 
mechanism(s) underlying these epimutations still remains to be established, it has 
been suggested that a trans-acting factor (modifier) may be involved (Hesson et al.,
2010), which could explain the epimutation reversibility between generations and 
the non-Mendelian inheritance patterns observed. In 2006 Chan et al. reported for 
the first time a germline MSH2 epimutation in a three-generation family presenting 
with Lynch-associated tumors and varying levels of MSH2 methylation in normal 
blood and rectal mucosa-derived cells. At that time, the mechanism underlying this 
inherited epimutation remained elusive.
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Epimutation and transcriptional read-through
The above findings have raised the intriguing possibility that in a significant proportion 
of families with colorectal cancer susceptibility may have an epigenetic basis. Based 
on their results, Chan et al. (2006) hypothesized that the observed MSH2 epimutation 
could provide a first hit towards colorectal cancer development in the family studied. 
Through high-resolution copy number profiling, Ligtenberg et al. (2009) encountered 
micro-deletions in the 3’ region of the EPCAM gene located upstream of the MSH2 
gene in four Dutch mismatch repair-deficient families. The epithelial cell adhesion 
molecule EPCAM is highly expressed in normal epithelial cells and serves as a 
prognostic marker in various carcinomas. They also were able to show that, as a 
result of these micro-deletions, the transcription-terminating polyadenlyation signals 
in the EPCAM gene were lost, leading to extended transcription into the MSH2 gene. 
Subsequently, it was found that all patients with a micro-deletion exhibited an in 
cis hyper-methylation of the MSH2 promoter in the microsatellite-positive tumors 
as well as in their normal epithelial tissues, thus showing a strong correlation with 
EPCAM expression levels. As such, 3’ end EPCAM deletion represents a novel 
type of epigenetic germline mutation that leads to tissue-specific inactivation 
of the MSH2 gene. Strikingly, a very similar deletion and concomitant promoter 
silencing mechanism was found in the family originally described by Chan et al., 
thus corroborating the results obtained (Chan et al., 2006, Ligtenberg et al., 2009). 
Furthermore, screening of an additional cohort of unexplained microsatellite-positive 
MSH2-deficient cases from the Netherlands revealed that 40% of them can be 
explained by such deletions (Ligtenberg et al., 2009). EPCAM deletion carriers have 
a high risk of developing colorectal cancer, comparable to that of MLH1 or MSH2 
mismatch repair gene mutation carriers. The risk of endometrial cancer is, however, 
significantly lower (Kempers et al., 2011). Currently, there are no indications that loss 
of one allele of the EPCAM gene itself contributes to the tumor phenotype in these 
families, but it has been reported that homozygous inactivation of EPCAM results 
in congenital tufting enteropathy resulting from epithelial dysplasia (Sivagnanam et 
al., 2008).
Aim and outline of the thesis
At the onset of this work, CNVs were clearly outnumbered by point mutations 
as a cause of cancer predisposition in most high-risk cancer syndromes. Their 
contribution, however, might be underestimated since targeted copy number 
analyses were rarely performed. Therefore, we hypothesized that application of 
copy number profiling to unexplained high-risk cancer families might serve as an 
attractive approach to identify novel moderate- to high-penetrance susceptibility 
genes. The aim of this thesis was to detect such genes in colorectal cancer families 
with unexplained etiologies. To achieve this goal, we performed high-resolution 
genomic profiling of germline DNA in a selected discovery cohort of index patients 
from 41 independent families diagnosed with microsatellite stable colorectal cancer 
without polyposis (Chapter 2). By using this approach, we identified submicroscopic 
(100-160 kb) copy number abnormalities in six index patients from different families 
(15%), affecting either a single gene or only a limited number of genes. In chapter
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3 we describe the involvement of one of these genes, PTPRJ, in human colorectal 
cancer predisposition, including the elucidation of the underlying epigenetic gene 
silencing mechanism, suggesting that CNV-based epimutations may serve as a more 
general mechanism in colorectal cancer predisposition. In Chapter 4, we focused on 
another newly identified candidate locus, KIAA1797/miR-491, and found that it was 
recurrently affected in early-onset and familial colorectal cancer patients. In Chapter 
5, we assessed the occurrence and frequency of miRNA CNVs in a cohort of early- 
onset familial colorectal cancer patients and a matched cohort of unaffected controls. 
The variability and recurrence of EPCAM deletions in Lynch syndrome patients is 
described in Chapter 6. Finally, we discuss our results in Chapter 7 and conclude 
that genome-wide copy number analysis in carefully selected unexplained cases at 
risk for hereditary colorectal cancer may serve as an alternative approach to identify 
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In the majority of colorectal cancers (CRC) under clinical suspicion for a hereditary 
cause, the disease-causing genetic factors are still to be discovered. In order to 
identify such genetic factors we stringently selected a discovery cohort of 41 CRC 
index patients with microsatellite-stable tumors. All patients were below 40 years of 
age at diagnosis and/or exhibited an overt family history. We employed genome-wide 
copy number profiling using high-resolution SNP arrays on germline DNA, which 
resulted in the identification of novel copy number variants (CNVs) in 6 patients (15%) 
encompassing, among others, the cadherin gene CDH18, the bone morphogenetic 
protein antagonist family gene GREM1, and the breakpoint cluster region gene BCR. 
In addition, two genomic deletions were encountered encompassing two microRNA 
(miRNA) genes, miR-491/KIAA1797 and miR-646/AK309218. None of these CNVs 
has previously been reported in relation to CRC predisposition in humans, nor were 
they encountered in large control cohorts (>1,600 unaffected individuals). Since 
several of these newly identified candidate genes may be functionally linked to CRC 
development, our results illustrate the potential of this approach for the identification 





Colorectal cancer (CRC) is the second most common cause of cancer-related 
death in the Western world in terms of both incidence and mortality rate. A positive 
family history of CRC is observed in about 20 to 25% of the cases (de la Chapelle
2004). Nevertheless, high-penetrance germline mutations in the APC and MUTYH 
genes and the mismatch repair genes MLH1, PMS2, MSH2 and MSH6 account for 
less than 5% of hereditary cases (Aaltonen et al., 2007). It is generally assumed 
now that the majority of the remaining genetic factors involve moderate- to low- 
penetrance genomic variations (Kemp et al., 2004). Considerable efforts to identify 
these variations by genome-wide association studies (GWAS) have recently become 
successful with the availability of high-density genotyping microarrays. Thus far, 
this approach has led to the identification of 14 low-penetrance CRC susceptibility 
loci (Speicher et al., 2010), thereby revealing only a part of the remaining genetic 
susceptibility (Cazier and Tomlinson, 2010). An alternative and comprehensive 
strategy to identify novel predisposing genes involves the screening of individual 
patients for the presence of germline copy number variants (CNVs), i.e., deletions 
or duplications, using high-resolution genomic profiling. In the past, several CNVs 
affecting high-penetrance cancer predisposing genes have already been reported, 
including the BRCA1 and BRCA2 genes, the VHL gene, the APC gene, and a variety 
of mismatch repair genes (Petrij-Bosch et al., 1997, Wijnen et al., 1998, Wagner et 
al., 2003, Plaschke et al., 2003, Bunyan et al., 2004, Michils et al., 2005). In addition, 
we recently found that constitutional 3’ deletions of the EPCAM gene can lead to 
allele-specific epigenetic silencing of the downstream mismatch repair gene MSH2 
(Ligtenberg et al., 2009). Based on these observations, we have hypothesized that 
CNVs that lead to the disruption and/or silencing of critical genes could result in 
moderate- to high-penetrance forms of cancer predisposition (Kuiper et al., 2010). 
As such, genome-wide analysis of CNVs in germline DNA of CRC patients and 
close relatives can be used as a strategy to discover novel targets involved in the 
predisposition and/or initiation of CRC. Here, we report the identification of germline 
CNVs affecting novel candidate CRC susceptibility genes in a discovery cohort of 




Our study included patients who were diagnosed with microsatellite-stable (MSS) 
CRC without polyposis. As a discovery cohort for our initial copy number screen 
we selected 41 CRC patients under the suspicion for hereditary or familial CRC 
because they were diagnosed at or below the age of 40, diagnosed below the age 
of 50 with at least two first-degree relatives with CRC, diagnosed below the age of 
50 with an apparent recessive inheritance pattern (i.e., a horizontal transmission 
pattern: multiple affected siblings from unaffected parents), or diagnosed below the 
age of 60 with at least three first-degree relatives with CRC. A validation cohort was 
used consisting of 248 CRC patients diagnosed with early-onset and/or familial CRC 
from both the Netherlands and Germany. For sequence analysis, we used a subset 
of 96 patients from this cohort, all diagnosed below the age of 40. All patient material 
was obtained with informed consent.
SNP-based array CGH and copy number analysis
Genomic DNA extracted from peripheral blood cells of 41 CRC index patients was 
hybridized on single nucleotide polymorphism (SNP) 250k (32 patients) or SNP 6.0 
(9 patients) Affymetrix GeneChip arrays, according to standard protocols provided by 
the manufacturer (Gene Chip Mapping 500K and 6.0 Assay manual). In accordance 
with Minimum Information About a Microarray Gene Experiment (MIAME) guidelines, 
CEL files of the microarray data were deposited in the GEO repository (http://www. 
ncbi.nlm.nih.gov/geo/query/, accession number GSE13429). For SNP 250k arrays, 
copy number analysis was performed using the public domain software package 
CNAG (Copy Number Analyzer for Affymertix GeneChip Mapping arrays), version 
2.0 (Nannya et al., 2005) by processing each 250k array against at least five best-fit 
reference samples. For SNP 6.0 arrays, copy number analysis was performed by 
processing the samples in a batch-wise fashion using the Affymetrix Genotyping 
Console v2.1 software (Ligtenberg et al., 2009). The Hidden Markov Model (HMM) 
available within both software packages was used to determine the CNV states and 
their breakpoints. Based on a previous study, in which we determined the amount 
of SNPs necessary to get a statistical power of 95% (Hehir-Kwa et al., 2007), we 
excluded copy number abnormalities smaller than four consecutive probes for losses 
and smaller than seven consecutive probes for gains. In order to exclude aberrations 
representing normal copy number variation the identified copy number variants were 
compared with those reported in the Database of Genomic Variants (http://projects. 
tcag.ca/variation/) (Iafrate et al., 2004), and those listed in our in-house database. 
This in-house database contains genomic copy number variations detected in 
peripheral blood DNA of healthy controls that were hybridized to Affymetrix 250K 
SNP arrays (n>1000) or SNP6.0 arrays (n=604). Hybridization and data processing 
was performed following the same procedures as for our patient cohorts (see above).
Multiplex ligation-dependent probe amplification
To validate the initial SNP-based CNVs, and to screen additional cohorts of CRC 
patients for these CNVs in a high-throughput mode, we employed Multiplex Ligation-
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dependent Probe Amplification (MLPA) (Schouten et al., 2002). MLPA probes 
were designed for five selected candidate genes, i.e., CDH18, GREM1, BCR, hsa- 
mir-491/KIAA1797 and hsa-mir-646/AK309218, according to guidelines provided 
by MRC-Holland (Amsterdam, The Netherlands). Ten probes were combined in 
one MLPA assay along with three standard control probes in two different genes,
i.e., VIRP2 and KIAA0056. A total of 200 ng of genomic DNA was used in each 
MLPA reaction. Probe mix and hybridization buffer (MRC-Holland, Amsterdam, 
The Netherlands) were added in equal amounts to the genomic DNA followed by 
heat denaturation and overnight hybridization of the probes at 60°C. Subsequently, 
ligation was performed after hybridization and the ligation products were amplified 
by PCR using either a 6-FAM or a NED fluorophore labeled primer set. Amplification 
products were quantified and identified by capillary electrophoresis on an ABI 3730 
genetic analyzer (Applied Biosystems, Forster City, CA, USA). Normalization of the 
data was performed by dividing the peak area of each probe by the average peak 
area of the control probes. This normalized peak pattern was divided by the average 
peak pattern of all samples in the same experiment. The resulting values were 
approximately 1.0 for every wild-type peak, 0.5 for heterozygous deletions, and 1.5 
for heterozygous duplications.
Genomic real-time quantitative PCR
Genomic real-time quantitative PCR (qPCR) was performed on a 7500 Fast Real­
Time PCR System (Applied Biosystems, Forster City, CA, USA) using SYBR Green- 
based quantification according to the manufacturer’s protocol (Bio-Rad, Veenendaal, 
the Netherlands). All PCR products, including those targeting three control regions, 
were between 80 and 120 bp. Each primer pair was validated in triplicate using serial 
genomic DNA dilutions resulting in end concentrations equivalent to 400, 200, 100, 
50, and 25 pg/^l DNA. Genomic qPCR quantifications were performed in duplicate 
on 1 ng/^l DNA and included a blank (water) control. All threshold cycle (Ct) values 
were within the range of DNA dilutions used to validate the primers. The melting 
curves of all PCR products showed a single PCR product, and blank controls were 
negative. DNA copy number differences between two samples were calculated by 
the 2AACt method (Livak et al., Pfaffl, 2001) and were expressed as the averaged 
intensity ratio between the targeted region and controls.
Sequence analysis
Genomic sequencing of the miRNA genes hsa-mir-491 and hsa-mir-646 (miRBase 
accession numbers MI0003126 and MI0003661; http://microrna.sanger.ac.uk/) was 
performed using PCR primers in conjunction with a 3700 DNA Analyzer (Applied 
Biosystems, Forster City, CA, USA) using standard procedures. Mutation analysis 




Identification o f novel CNVs in a discovery cohort o f CRC index patients
We performed a genome-wide screen for CNVs in germline DNA of a selected 
discovery cohort of index patients from 41 independent families diagnosed with 
microsatellite stable CRC without polyposis, fulfilling one of the following inclusion 
criteria: 1) diagnosed at or below the age of 40, 2) diagnosed below the age of 50 
with at least two first-degree relatives with CRC, 3) diagnosed below the age of 
50 with an apparent recessive inheritance pattern, or 4) diagnosed below the age 
of 60 with at least three first-degree relatives with CRC. We anticipated that these 
stringent selection criteria would increase the chance of finding moderate- to high- 
penetrance CRC predisposing genetic variants. DNA was extracted from peripheral 
blood cells of these index patients, hybridized to Affymetrix GeneChip SNP 250k or 
SNP 6.0 arrays, and analyzed for the presence of CNVs. Unique candidate CNVs 
were identified in six patients, ranging in size from 27 kb to 158 kb, each targeting one 
or two genes through (intra)genic deletions and/or duplications (Table 1). Using high­
resolution multiplex ligation-dependent probe amplification (MLPA) and/or genomic 
real-time qPCR, we were able to validate the CNVs identified by our array-based 
profiling approach (Table 1). None of these CNVs has previously been reported 
in relation to CRC predisposition in humans, nor were they identified as regions 
exhibiting harmless genomic copy number variation as listed in the Database of 
Genomic Variants (http://projects.tcag.ca/variation/) (Iafrate et al., 2004) and our in­
house database, which contains data from genomic microarray analyses of >1,600 
unaffected individuals.
Exon 2 deletion in the cadherin gene CDH18
In patient #39, who was diagnosed with rectal carcinoma at the age of 49, we 
identified a deletion in the classical type-II cadherin gene CDH18 (formerly known 
as CDH14) (Figure 1; II:1). Cadherins are transmembrane proteins involved in cell­
cell adhesion. Subsequent MLPA-based validation revealed that the deletion only 
comprised exon 2 of the CDH18 gene, thereby disrupting its open reading frame. In 
addition, we were able to establish that a brother of this patient (II:3), who died from 
a colorectal adenocarcinoma at the age of also 49, carried exactly the same deletion 
(Figure 1C). Despite the fact that no parental DNA was available for analysis, the 
finding of the same deletion in the brother of the patient indicates that the CNV must 
be inherited from one of the parents. In order to assess the possibility of a recessive 
mode of inheritance, we sequenced the non-deleted germline CDH18 allele from 
the index patient for the presence of pathogenic mutations. No such mutations were 
found, thus suggesting an autosomal dominant and/or haplo-insufficient mode of 
inheritance. This suggestion is in agreement with our failure to detect, next to the 
deletion, second-hit mutations in the tumor tissue of the index patient (data not 
shown).
Duplication encompassing the bone morphogenetic protein antagonist GREM1
In another patient (#22), who was diagnosed with sigmoid colon carcinoma at the age 




Table 1. Characteristics of validated micro-deletions/duplications in six CRC index patients
Patient # Age of 
onset
Aberration Cytoband CNV size Validation Identified
carriers
# genes1 Candidate genes
15 33 Loss 9p21.3 158 kb MLPA Mother 2 KIAA1797; miR-491
22 35 Loss 8p23.1 27 kb qPCR NA2 1 MFHAS1
22 35 Gain 15q 13.3 57 kb MLPA NA2 2 GREM1, SCG5
25 36 Loss 20q13.33 117 kb MLPA NA2 2 AK309218; miR-646
26 36 Gain 11 p11 156 kb MLPA Father 1 PTPRJ
34 40 Gain 22q 11.23 109 kb MLPA Mother 1 BCR






in c lu d e s  num ber of known prote in-coding genes taken from the NCBI mRNA reference sequences collection (RefSeq) and m iRNA 
genes. A d d itio n a l m aterial from  relatives was not available (NA).
family gene GREM1 (Figure 2A). GREM1 is known for its antagonistic activity 
towards bone morphogenetic proteins (BMPs) through the TGF-beta signaling 
pathway (Jaeger et al., 2008). Subsequent MLPA-based validation revealed that 
the duplication encompassed the entire GREM1 gene, in addition to exons 3 to 6 
of the neighboring secretogranin gene SCG5 (Figure 2A). Additionally, we found a 
second CNV, a deletion, in the same patient affecting the 3’ UTR of the malignant 
fibrous histiocytoma amplified sequence gene MFHAS1 (also known as MASL1), 
an interactor of proteins related to cell cycle progression and a known target for 
genomic amplification as well as chromosomal translocation (Sakabe et al., 1999). 
This 3’ UTR deletion was validated by genomic qPCR (Figure 2B) and may result in 
loss of gene expression or the generation of an aberrant fusion transcript.
Intragenic duplication affecting the breakpoint cluster region gene BCR
In patient #34, who was diagnosed with rectal carcinoma at the age of 40, we 
found a duplication affecting the breakpoint cluster region gene BCR (Figure 2C). 
Translocations affecting BCR are a hallmark of chronic myeloid leukemia and some 
acute leukemias (Perrotti et al., 2010). Subsequent MLPA analysis revealed an 
intragenic duplication encompassing the 3’ moiety of the BCR gene, with a breakpoint 
located in intron 6 (Figure 2C). This duplication may affect the normal function of the 
BCR protein through the generation of aberrant (fusion) transcripts.
Deletion o f two miRNA genes
In our screen we also identified germline deletions in two miRNA genes, hsa-mir-491 
and hsa-mir-646, located within the hypothetical protein coding genes KIAA1797 
and AK309218 in patients #15 and #25, respectively (Figure 2D,E). These patients 
were diagnosed with rectal carcinoma at the ages of 33 and 36 years, respectively. 
MiRNAs are regulatory non-coding RNAs, usually 21 to 24 nucleotides in length, and 
are known to be involved in many cellular processes, including cancer (Garzon et 
al., 2009). Subsequent MLPA-based validation revealed that the deletion in patient 
#15, in addition to hsa-mir-491, also encompassed exons 4 to 21 corresponding to 
the hypothetical protein KIAA1797 (Figure 2D), thereby disrupting its open reading 
frame. The deletion of hsa-mir-646 (patient #25) includes intron 3 corresponding to 
the hypothetical protein AK309218 and, as such, could affect normal splicing of this 
gene (Figure 2E). Genomic deletions in miRNAs may result in haplo-insufficiency 
and/or dosage effects of its target transcripts and, as such, play a role in cancer 
development. Recently, it was found that germline mutations and SNPs in miRNAs 
may also be involved in cancer susceptibility (Calin et al., 2005, Jazdzewski et al.,
2008). Therefore, we performed hsa-mir-491 and hsa-mir-646 mutation screens in 
an independent cohort of 96 patients, all diagnosed with microsatellite stable CRC 
below the age of 40. This screen yielded several polymorphisms in the stemloop 
structure and the mature miRNA encoded by hsa-miR-646.
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Figure 1. Deletion within the type-II cadherin gene CDH18. (A) Pedigree showing two 
brothers (II:1 and II:3) with colorectal cancer, both at 49 years of age (CRC49; closed 
symbols). Patient II:1 is index patient #39 (arrow). Deceased persons are indicated by a 
diagonal line. (B) CNAG plot of the short arm of chromosome 5 in patient #39 and structural 
organization of the CDH18 gene, showing an intragenic deletion of exon 2 which disrupts 
the open reading frame of the gene. (C) Validation of the genomic deletion by MLPA in both 
germline (blue line) and tumor (green line) DNA of patient II:1, as well as in the tumor DNA 
of his brother (II:3; red line). Black lines represent normal control DNAs.
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Figure 2. Lesions identified in four familial and/or early-onset CRC patients. Left 
panels depict whole chromosome genomic plots showing the candidate CNVs (indicated by 
arrow heads) affecting SCG5 and GREM1 (A), MFHAS1 (B), BCR (C), KIAA1797/miR-491 
(D) and AK309218/miR-646 (E). Log2 test-over-reference ratios of hybridization signals of 
individual SNPs are indicated by red dots. Blue lines represent a ten SNP moving average. 
Right panels show the validation of each of the identified CNVs by MLPA (A,C,D,E; purple 




Using high-resolution SNP-based copy number profiling in a discovery cohort of 41 
carefully selected CRC index patients, we identified novel rare germline CNVs in six 
of them, affecting single protein coding genes as well as genes encoding miRNAs 
(Tablel). None of these CNVs has previously been reported in relation to CRC 
predisposition in humans, nor were they encountered as rare polymorphisms in large 
control cohorts. Nevertheless, we consider them as interesting candidates since 
several of the genes affected can be functionally linked to CRC susceptibility. It has 
been reported, for example, that the bone morphogenetic protein antagonist GREM1 
harbors SNPs that are strongly associated with an increased CRC risk (Jaeger et 
al., 2008). Our current finding of a duplication affecting the entire GREM1 gene may 
suggest over-expression of the protein in specific tissues such as colon, thereby 
initiating CRC tumor formation. Very recently, we found that a partial duplication 
affecting the candidate tumor suppressor protein tyrosine phosphatase PTPRJ gene 
may evoke CRC susceptibility through epigenetic silencing of the intact copy of the 
gene (Table 1, patient #26) (Venkatachalam et al., 2010b). Previously, others have 
identified PTPRJ as the target gene in the colon cancer susceptibility locus Scc1 in 
a recombinant congenic mouse strain (Ruivenkamp et al., 2002). Interestingly, both 
PTPRJ and GREM1 have been associated with the development of (non-hereditary) 
sporadic CRCs as well. PTPRJ, for example, has frequently been found to be deleted 
in tumor DNA of sporadic CRCs (Ruivenkamp et al., 2002, Ruivenkamp et al., 2003, 
luliano et al., 2004). In aberrant crypt foci, the earliest neoplastic lesions of the colon, 
deletions in PTPRJ were also frequently encountered, thus suggesting a major role 
of this gene in early colon neoplasia (Luo et al., 2006). GREM1 expression has been 
found to be up-regulated during the development of a subset of sporadic CRCs, and 
BMP antagonists have been identified as candidate signaling components that make 
up the intestinal epithelial stem cell niche (Kosinski et al., 2007). The breakpoint 
cluster region gene BCR, which was affected by a partial duplication in one of our 
patients, was previously reported to be located within an instability-associated 
region that is affected in one-third of sporadic human CRCs (Bartos et al., 2007). 
miR-491, another candidate identified by our approach, has been shown to induce 
apoptosis by targeting Bcl-X(L) in CRC cells (Nakano et al., 2010). Together, these 
data suggest that at least a subset of our newly identified germline CNVs may play 
a role in CRC susceptibility and/or (early) CRC development.
Another interesting candidate that we identified is the classical type-ll cadherin 
gene CDH18. Cadherins are known to play a crucial role in tumor initiation and 
progression. In fact, germline mutations in the type-l cadherin gene CDH1 are the 
underlying cause of hereditary diffuse gastric cancer (HDGC) (Guilford et al., 1998, 
Guilford et al., 1999), and SNPs in the CDH1 gene are associated with an increased 
CRC risk (Houlston et al., 2008). The CDH18 gene was also found to be mutated in 
sporadic CRCs (Wood et al., 2007). CDH18 was previously isolated as an interactor 
of p-catenin and, therefore, appears to be linked to the Wnt signaling pathway, an 
important CRC pathway (Shibata et al., 1997). This putative involvement of CDH18 
is particularly interesting since also the PTPRJ encoded protein DEP1 happens to 
be involved in the regulation of cell-cell adhesion through de-phosphorylation of the
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cadherin-catenin complex at adherens junctions (Goss and Groden, 2000, Grazia et 
al., Jandt et al., 2003, Kellie et al., 2004, Lilien and Balsamo, 2005, Ostman et al., 
2006). Deregulation of cadherin-catenin complexes has been shown to contribute 
to tumor development by affecting the adhesion of epithelial cells in e.g. the colon 
(Goss and Groden, 2000). Consequently, also CDH18 may be functionally linked to 
known CRC pathways.
The identification of unique gene-disrupting CNVs in 6 out of the 41 unexplained 
early-onset and/or familial CRC cases tested, indicates that germline copy number 
variants may indeed play a significant role in CRC susceptibility and, as such, may 
fill in at least part of the so-called missing heritability gap (Manolio et al., 2009). 
However, further evidence indicating that the candidate genes identified in this 
study indeed contribute to the CRC susceptibility requires the identification of 
additional independent cases harboring CNVs or pathogenic mutations in these 
genes. A locus-specific copy number screen in all these candidate genes (excluding 
MFHAS1) in the validation cohort of 248 early-onset and/or familial CRC cases thus 
far revealed one additional, but clearly distinct, genomic duplication in the PTPRJ 
gene (Venkatachalam et al., 2010b), suggesting that these CNVs may indeed be 
recurrent, but that their frequency may be relatively low. Obviously, a screen of much 
larger CRC validation cohorts is needed to properly address this point. The additional 
observation that not all the carriers of CNVs in the candidate genes developed CRC 
is indicative for a moderate penetrance.
In Li-Fraumeni syndrome families, a genome-wide copy number screen revealed 
that CNVs in TP53 mutation carriers was higher as compared to unaffected controls, 
and that these CNVs also involved several cancer-related genes that may act as 
modifiers (Shlien et al., 2008). A similar role might also apply for the CNVs found in 
our study. In fact our finding of one patient with two candidate CNVs is in agreement 
with an anticipated moderate penetrance, where both these loci could be involved 
in CRC susceptibility. For example, these two CNVs may have been derived from 
both parents, thereby contributing to an increase in CRC susceptibility in an additive, 
possibly modifying fashion. Unfortunately, no parental material was available to test 
this option.
In summary, our high-resolution screen for germline CNVs in a discovery cohort of 
CRC patients has revealed several novel candidate CRC susceptibility genes. Even 
though the significance of CNVs in genomic disorders and sporadic tumors is fully 
appreciated, their role in cancer predisposition is as yet poorly explored (Kuiper et 
al., 2010). Our results vividly illustrate that genome-wide copy number analysis in 
carefully selected unexplained cases at risk for hereditary cancer may serve as an 




Germline epigenetic silencing of the tumor 
suppressor gene PTPRJ in early-onset 
familial colorectal cancer
Ramprasath Venkatachalam,* Marjolijn JL Ligtenberg,* Nicoline 
Hoogerbrugge,* Hans K Schackert, Heike Görgens, Marc-Manuel Hahn, 
Eveline J Kamping, Lilian Vreede, Eveline Hoenselaar, Erica van der Looij, 
Monique Goossens, Mike Churchman, Luis Carvajal-Carmona, Ian PM 
Tomlinson, Diederik RH de Bruijn, Ad Geurts van Kessel and
Roland P Kuiper
*These authors contributed equally to this work
This is an extended version of the manuscript published in 
Gastroenterology 139:2221-2224, 2010

Background and Aims: Recently we showed that 3’ deletion of the EPCAM gene 
leads to allele-specific epigenetic silencing of the neighbouring MSH2 gene in Lynch 
syndrome patients. The underlying mechanism was found to involve MSH2 promoter 
hypermethylation mediated by transcriptional read-through, thus providing an 
explanation of how colorectal cancer (CRC) susceptibility in these families could be 
inherited. Here we have investigated whether similar copy number variation (CNV)- 
based silencing mechanisms may underlie unexplained familial CRC cases. 
Methods: A genome-wide SNP array-based screen for constitutional CNVs was 
performed on a carefully selected cohort of microsatellite stable CRC patients 
without polyposis. Epigenetic silencing of one of the candidate genes showing CNV 
was established using allele-specific transcription and bisulfite sequencing.
Results: We identified a constitutional duplication encompassing the 5’ end of the 
PTPRJ gene, which was absent in >2,650 non-affected individuals. The duplication 
showed a head-to-tail in-tandem configuration. Transcriptional read-through and 
concomitant allele-specific silencing of the downstream PTPRJ locus by promoter 
hypermethylation was demonstrated in patient-derived tissues, but not in controls. 
Targeted screening of an independent cohort of unexplained familial CRC patients 
revealed a second case with again a partial, but not identical, PTPRJ duplication and 
a concomitant promoter hypermethylation. PTPRJ is a tumor suppressor gene that 
was previously identified as a CRC susceptibility gene in mice.
Conclusions: Our data indicate that PTPRJ may predispose to CRC through 
epigenetic gene silencing in humans, suggesting that CNV-based epimutations may 





Mendelian inherited cancer syndromes are frequently caused by germline mutations 
or copy number variations (CNVs) in high-penetrance genes (Foulkes, 2008, Kuiper 
et al., 2010). Germline mutations in APC, for example, result in familial adenomatous 
polyposis (FAP), whereas mutations in one of the mismatch repair genes MLH1, 
MSH2, MSH6 or PMS2 cause Lynch syndrome (de la Chapelle 2004, Aaltonen et 
al., 2007). Increasing evidence suggests that epigenetic modifications may also play 
a role in cancer predisposition. Several reports describe mono-allelic methylation of 
the MLH1 promoter in peripheral blood cells of individuals that meet the criteria for 
Lynch syndrome, but lack germline mutations in the MLH1 gene (Gazzoli et al., 2002, 
Hitchins et al., 2007). Occasionally, these so-called epimutations have been found to 
be transmitted over more generations but, as yet, the mechanism underlying these 
epimutations still remains to be elucidated (Hitchins et al., 2007, Morak et al., 2008, 
Hesson et al., 2010). Chan et al. for the first time reported an inherited germline 
MSH2 epimutation in a family presenting with Lynch-associated tumors and mosaic 
MSH2 hypermethylation pattern in normal tissues (Chan et al., 2006). Recently, we 
resolved the underlying mechanism of this defect by identifying 3’-end deletions 
in the EPCAM gene, located upstream of MSH2. These truncating deletions lead 
to transcriptional read-through and subsequent allele-specific methylation of the 
MSH2 promoter (Ligtenberg et al., 2009). Based on these findings and literature 
data we hypothesize that constitutional gene silencing due to DNA copy number 
based epimutations may be a more general cause of disease susceptibility, including 
colorectal cancer. To test this hypothesis, we performed a genome-wide DNA copy 
number screen in a carefully selected cohort of patients diagnosed with microsatellite 
stable CRC without polyposis. By using this approach, we identified germline 
epigenetic silencing in an early-onset CRC patient induced by a micro-duplication in 




All patients included in our study carried microsatellite-stable tumors without 
polyposis. As a discovery cohort for our initial copy number analysis we selected 
32 Dutch patients that were diagnosed with CRC at or below the age of 40 or with 
a recessive mode of inheritance (i.e., a horizontal transmission pattern: multiple 
affected siblings from unaffected parents). Furthermore, we used a cohort of 1,456 
familial CRC patients from the Netherlands, Germany and the UK for screening 
of recurrent PTPRJ lesions. Peripheral blood cells of II:1 and III:4 were used to 
generate Epstein-Barr Virus (EBV) immortalized lymphoblastoid cell lines using 
standard procedures. All patient material was obtained with informed consent.
SNP arrays and copy number analysis
Genomic DNA from peripheral EDTA blood of 32 CRC patients was hybridized to 
SNP 250k Affymetrix GeneChip arrays (Affymetrix Inc., Santa Clara, CA, USA), 
according to the protocol provided by the manufacturer (Gene Chip Mapping 500K 
Assay manual). Copy number analyses were performed using the public domain 
software package CNAG (Copy Number Analyzer for Affymertix GeneChip Mapping 
arrays), version 2.0 (Nannya et al., 2005). Next to visual inspection, the Hidden 
Markov Model available within the CNAG software package was used to score for 
CNVs. Peripheral blood cell-derived DNA from an additional patient from Dresden, 
Germany was hybridized to a SNP6.0 array, containing 1.8 million probes, as 
reported before (Ligtenberg et al., 2009). Based on a previous study (Hehir-Kwa et 
al., 2007), we excluded CNVs smaller than four consecutive SNPs for losses and 
smaller than seven consecutive SNPs for gains. The identified CNVs were compared 
with those previously reported in 270 unaffected HapMap individuals (Redon et al., 
2006), and those listed in our in-house database, in order to exclude normal copy 
number variation.
Multiplex ligation-dependent probe amplification (MLPA)
To validate the initial SNP-based CNVs, and to screen large cohorts of CRC patients 
for recurrence of these CNVs in a high-throughput mode, we employed Multiplex 
Ligation-dependent Probe Amplification (MLPA) (Schouten et al., 2002). MLPA 
probes were designed for PTPRJ, according to guidelines provided by MRC-Holland 
(Amsterdam, The Netherlands). Ten probes were combined in one MLPA assay along 
with four standard control probes in three different genes, i.e., VIRP2, MRPL41, and 
KIAA0056. A total of 200 ng of genomic DNA was used in each MLPA reaction. 
Probe mix and hybridization buffer (MRC-Holland) were added in equal amounts to 
the genomic DNA followed by heat denaturation and overnight hybridization of the 
probes at 60°C. Subsequently, ligation was performed after hybridization and the 
ligation products were amplified by PCR using either a 6-FAM or a NED fluorophore 
labeled primer set. Amplification products were quantified and identified by capillary 
electrophoresis on an ABI 3730 genetic analyzer (Applied Biosystems, Forster 
City, CA, USA). Normalization of the data was performed by dividing the peak area 
of each probe by the average peak area of the control probes. This normalized
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Chapter 3
peak value was divided by the average peak values of all the samples in the same 
experiment. The resulting values were approximately 1.0 for wild-type peaks, 0.5 for 
heterozygous deletions, and 1.5 for heterozygous duplications.
Sequence analysis
Genomic sequencing using PCR primers designed for all PTPRJ exons of the first 
validation cohort was performed on amplified DNA by Macrogen Inc. (Seoul, South 
Korea). A 3700 DNA Analyzer (Applied Biosystems) at the department of Human 
Genetics Nijmegen was used for all other sequence analyses. Data analyses were 
carried out using the Vector NTI software package (Invitrogen, Carlsbad, CA, USA) 
as reported before (Ligtenberg et al., 2009). Annotations for base pair changes in 
protein-coding genes were based on GenBank accession number NM_002843.3 
(PTPRJ).
Pyrosequencing analysis
To determine the allele-specific expression of the PTPRJ gene, standard 
pyrosequencing (PSQ) was performed according to the protocol of the manufacturer 
(Qiagen, Venlo, The Netherlands; PSQ96MA), with minor modifications (Ruiter et 
al., 2007).
Vectorette PCR
A vectorette-PCR procedure was employed as reported before (Kuiper et al., 2003), 
with minor modifications. Briefly, Sau3A-digested DNAs from peripheral blood cells 
of patient III:4 and an unrelated normal donor were ligated overnight at 16°C to 
phosphorylated Vectorette Top and bottom strand primers. The resulting vectorette 
libraries were amplified in a hemi-nested PCR reaction using an universal primer 
in conjunction with sequence-specific primers. Subsequently, PCR fragments were 
separated on agarose gels, purified, ligated into a pGemT vector (Promega, Leiden, 
The Netherlands) and sequenced.
Methylation analysis
Bisulfite treatment of DNA samples was performed as described before (Ligtenberg 
et al., 2009). Primers for bisulfite sequencing of genomic targets were deduced from 
the MethPrimer program (Li and Dahiya, 2002). PCR products were cloned into a 
pGemT vector (Promega) and ~25 individual clones were sequenced for evaluation 
of the methylation status of the respective selected targets.
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Results
PTPRJ duplication in an early-onset CRC patient
A genome-wide CNV screen was performed in a carefully selected cohort of 41 
independent index patients diagnosed with microsatellite stable CRC without 
polyposis. All subjects fulfilled at least one of the two following inclusion criteria: 
diagnosed at or below the age of 40 or diagnosed below the age of 50 with an 
apparently recessive mode of inheritance. DNA was extracted from peripheral blood 
cells of the index patients and hybridized to Affymetrix GeneChip 250k SNP arrays, 
according to standard procedures. Using this approach we identified candidate 
copy number variants (CNVs) in 15% of the cases, including an ~170kb intragenic 
duplication affecting the 5’ end of the protein tyrosine phosphatase gene PTPRJ 
on chromosome 11p11.2 (111:4; Figure 1A,B). This duplication was independently 
validated using multiplex ligation-dependent probe amplification (MLPA) analysis 
of the patient’s peripheral blood cells and tumor tissue, essentially as described 
previously (Ligtenberg et al., 2009) (Figure 1C). In addition, we found by MLPA that 
the father of the patient (II:1) carried the same duplication, indicative of a moderate 
penetrance scenario which may be influenced by additional susceptibility loci in the 
patient. The grandmother (I:2) had also suffered from CRC, but from her no material 
was available for further analysis. Thus far, copy number variants in the PTPRJ gene 
related to CRC predisposition have not been reported in the literature, nor were 
they identified as structural variants in healthy individuals listed in the Database of 
Genomic Variants (http://projects.tcag.ca/variation/) (lafrate et al., 2004) or in our 
in-house database, which contains high resolution genomic profiles of more than 
1,600 unaffected individuals. Furthermore, targeted MLPA screening of an additional 
cohort of 1,050 unaffected ethnicity-, gender- and age-matched controls failed to 
reveal any CNV affecting the PTPRJ gene. Together, this duplication was found to 
be absent in >2,650 controls, excluding the possibility that this is a common copy 
number polymorphism.
PTPRJ duplication results in an aberrant fusion transcript
In order to elucidate the biological consequences of this duplication, we first set out 
to establish the genomic location and orientation of the duplicated PTPRJ segment. 
To this end, we performed FISH analysis on patient-derived Epstein-Barr Virus 
(EBV) immortalized lymphoblastoid cells using BAC clone RP11-437J24 as a probe. 
By doing so, PTPRJ signals were detected only at the cognate site on the p-arm 
of chromosome 11, thus excluding integration elsewhere into the genome. In order 
to subsequently determine the exact integration site, we used quantitative PCR- 
based fine mapping in conjunction with linker-based vectorette PCR as reported 
before (Kuiper et al., 2003). Through this approach, we isolated a 180 bp fragment 
encompassing the breakpoints and its flanking regions. Sequencing of this fragment 
(Figure 1D) revealed that the duplicated PTPRJ segment, which encompasses 
the transcriptional control elements and exons 1 to 11, is present in a head-to-tail 
orientation directly upstream of the wild-type gene, with the breakpoint located ~12 
kb upstream of its transcription start site (position chr11:47946334, NCBI build 
hg18). An immediate consequence of this structural rearrangement could be that
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Figure 1. An inherited duplication affecting the protein tyrosine phosphatase gene PTPRJ. (A) Pedigree showing the index patient 
(lll:4  arrow) and her grandmother (l:2), both with colorectal cancer at 36 and 65 years of age, respectively (closed symbols). Deceased 
persons are indicated by a diagonal line. (B) Copy number profile of the short arm of chromosome 11 and structural organization of the 
PTPRJ gene, showing the position of the duplicated region affecting the 5’ part of the gene. (C) Validation and segregation analyses by 
MLPA showing that the constitutional duplication in the index patient (green line) is also present in its tumor DNA(blue line) and the germline 
DNA of the unaffected father (11:1 purple line; currently 71 years old). Germline DNA from the mother (ll:2 pink line) does not show the 
duplication. Black lines represent normal control DNAs. (D) Sequence analysis of the cloned -180 bp PCR fragment revealing the exact 







transcription of the duplicated PTPRJ gene segment, which lacks a polyadenylation 
signal, reads through into the downstream intact gene resulting in a fusion transcript. 
Indeed, using RT-PCR we were able to show that an aberrant transcript, in which 
exon 11 is spliced to exon 2 of the PTPRJ gene (Figure 2A-C), was present in 
lymphoblastoid cells, normal colon tissue and tumor tissue derived from the patient 
(111:4) and in lymphoblastoid cells derived from her father (II:1), but not in control 
cells. Consequently, the head-to-tail in tandem duplication of PTPRJ results in 
transcriptional read-through into the downstream intact copy of the gene.
Allele-specific epigenetic silencing o f the PTPRJ gene
This scenario reminiscences the allele-specific epigenetic silencing of the MSH2 
gene that we previously observed in Lynch syndrome patients (Ligtenberg et al.,
2009). We therefore hypothesized that this transcriptional read-through might have 
an effect on the expression of the PTPRJ gene in an allele-specific manner. To test 
this hypothesis, we made use of an informative single nucleotide polymorphism 
(SNP; rs4752904) present in exon 13 of the PTPRJ gene. The father of the patient, 
who passed on the duplication, was found to be homozygous (G-allele) for this 
SNP, whereas the patient was heterozygous (G/C; Figure 2D). Using cDNA (pyro) 
sequencing on lymphoblastoid cells of the patient, the mutant (G) allele was found 
to be expressed at very low to undetectable levels as compared to unrelated control 
lymphoblastoid cells carrying the same SNP (Figure 2D). In order to assess an 
epigenetic basis for the PTPRJ gene silencing event observed here, we performed 
DNA methylation assays. To this end, bisulfite sequencing of a region within 
the PTPRJ CpG island promoter (Figure 2A) was performed in patient-derived 
lymphoblastoid cells, normal colon tissue and tumor tissue, and in unrelated control 
tissues as described before (Ligtenberg et al., 2009). These analyses revealed a 
significant increase in PTPRJ promoter methylation in the patient-derived tissues 
as compared to the respective control tissues (Figure 2E and F). From these results 
we conclude that the constitutional genomic duplication, which was inherited by the 
early-onset CRC patient, has resulted in an allele-specific epigenetic silencing of the 
wild-type PTPRJ gene.
Identification o f recurrent PTPRJ duplications in early-onset patients
In order to obtain supporting evidence that the mono-allelic silencing of PTPRJ 
observed in this patient is associated with the early-onset of CRC, we performed a 
targeted MLPA screen in an additional cohort of 1,456 familial microsatellite stable 
CRC patients. We indeed detected an additional partial duplication of the PTPRJ 
gene in a female patient who was diagnosed with CRC in the sigmoid at 39 years of 
age (no affected family members). This duplication, which was found to be inherited 
from the patient’s mother, was 564 kb in size (as determined by SNP 6.0 array data) 
and excluded exon 1 of the gene, which encodes the signal sequence of this receptor- 
type protein. Although the exact genomic constitution of this duplication still remains 
to be established, we found through bisulfite sequencing that also in this case the 
PTPRJ gene promoter was hypermethylated, thus pointing at a very similar CNV- 
based epigenetic scenario. In addition, we performed a sequence mutation scan in 
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Figure 2. Germline epimutation of the protein tyrosine phosphatase PTPRJ gene 
induced by a constitutional micro-duplication. (A) Schematic representation of the 
head-to-tail in tandem micro-duplication encompassing exons 1-11 of the PTPRJ gene. 
Transcription of the duplicated segment reads through into exon 2 of the downstream 
intact copy of the gene, thereby inducing hypermethylation and subsequent silencing of 
its CpG island (CGI) promoter. (B) RT-PCR analysis using primers in exon 11 (P11F) and 
exon 3 (P3R) of the PTPRJ gene, revealing an aberrant fusion transcript (see also 2C) in 
lymphoblastoid cells (LC), normal colon mucosa (NC) and tumor (Tu) of the index patient 
(III:4) as well as in lymphoblastoid cells of her father (II:1), but not in an unaffected control 
(C) lymphoblastoid cells (LC). An exon 13 to exon 14 (P13F-P14R) RT-PCR product was 
used as input control. (C) Sequence analysis of the P11F-P3R RT-PCR fragment derived 
from patient III:4 showing the aberrant transcript fusion between exon 11 and exon 2. (D) 
Sequence of PTPRJ exon 13 using lymphoblastoid cell-derived genomic DNA showing a 
coding SNP rs4752904 (middle) which is heterozygous in the patient (III:4) and homozygous 
in the father (II:1), both carriers of the duplication. Sequencing of the expressed PTPRJ 
transcripts revealed that only the wild-type C-allele was expressed, whereas an unrelated 
heterozygous control sample showed normal bi-allelic expression. (E) and (F) Relative 
levels of methylation in lymphoblastoid cells (LC), normal colon mucosa (NC) and tumor 
(Tu) of the index patient (in duplo) and in nine unrelated controls as determined by bisulfite 
sequencing of an amplified region within the CpG island of the PTPRJ promoter. For each 
amplicon, 20-25 independent clones were sequenced. Depicted are the percentages of 
clones showing <30% methylation (white bars), 30-60% methylation (grey bars), and >60% 
methylation (black bars).
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the age of 40 years. Apart from several previously described SNPs (Ruivenkamp 
et al., 2002, Toland et al., 2008), no overt pathogenic nonsense and/or missense 
mutations were found. Together, our results show that PTPRJ is recurrently affected 




Our DNA copy number screen in a carefully selected cohort of CRC patients has 
revealed PTPRJ as a candidate CRC susceptibility gene. Thus far, copy number 
variants (CNVs) in the PTPRJ gene related to CRC predisposition have not been 
reported in the literature, nor were they identified as structural variants in healthy 
individuals. The identification of PTPRJ as a candidate CRC predisposition gene 
is remarkable since in a previous study Ptprj was identified as the target gene at 
the colon cancer susceptibility locus Scc1 in a recombinant congenic mouse strain 
(Ruivenkamp et al., 2002). Subsequent analyses revealed that human PTPRJ is 
deleted in several tumor types, including those from the colon (Ruivenkamp et al., 
2002, Ruivenkamp et al., 2003, luliano et al., 2004). PTPRJ deletions were also 
frequently encountered in aberrant crypt foci, the earliest neoplastic lesions of the 
colon, suggesting a major role of this gene in early colon neoplasia (Luo et al.,
2006). We assessed the tumor of our index patient for the presence of somatic 
mutations. No additional PTPRJ mutations were detected, thus suggesting a haplo- 
insuffiency scenario. This notion is fully concordant with data from sporadic colorectal 
adenocarcinomas harboring PTPRJ deletions, in which no second-hit mutations 
were found (Ruivenkamp et al., 2002).
PTPRJ encodes the density-enhanced phosphatase DEP-1 (also designated CD148), 
which is a widely expressed tumor suppressor involved in the control of cellular 
growth and transformation by antagonizing receptor tyrosine kinase activity (Ostman 
et al., 1994, Keane et al., 1996, Trapasso et al., 2000, Kovalenko et al., 2000, Palka 
et al., luliano et al., 2003, Massa et al., Trapasso et al., 2004, Balavenkatraman et 
al., 2006, Tarcic et al., 2009). DEP-1 has also been identified as a negative regulator 
of oncogenic Ras signaling (Omerovic et al., 2010). Furthermore, DEP-1 plays an 
important role in the regulation of cell-cell adhesion through dephosphorylation of the 
cadherin-catenin complex at adherens junctions (Goss and Groden, 2000, Grazia et 
al., Jandt et al., 2003, Kellie et al., 2004, Lilien and Balsamo, 2005, Ostman et al.,
2006). It has been reported that deregulation of cadherin-catenin complexes may 
contribute to tumor development by affecting the adhesion of epithelial cells in the 
colon and that SNPs in cadherin-1 (CDH1) gene are associated with CRC risk (Goss 
and Groden, 2000, Houlston et al., 2008). It has also been found that cadherin- 
catenin deregulation affects the Wnt signaling pathway, which is activated in the vast 
majority of colorectal tumors, by regulating the stability and sub-cellular localization 
of p-catenin (Fodde et al., 2001, Cavallaro and Christofori, 2004). Homozygous Ptprj 
knock-out mice developed normally and showed no signs of tissue abnormalities 
and/or increased tumor incidences (Trapasso et al., 2006), and a mutation scan of 
the entire protein tyrosine phosphatase gene family in 18 colorectal tumors failed to 
reveal any pathogenic mutations (Wang et al., 2004). Transgenic mice in which the 
intracellular catalytic domain of DEP-1 was replaced by enhanced green fluorescent 
protein, however, died at mid-gestation because of defects in vascular development, 
suggesting that the extracellular DEP-1 domain in these mice acts as a functional 
ligand that interferes with normal vascularization (Takahashi et al., 2003) and, as 
such, in tumor development.
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Germline methylation defects in Mendelian cancer syndromes have occasionally 
been reported but, until recently, the underlying mechanisms have remained poorly 
understood (Hesson et al., 2010). In concurrence with our previous elucidation of 
the mechanism underlying CNV-based MSH2 epimutations in a subgroup of Lynch 
syndrome patients with 3’ deletions of the EPCAM gene, we here report epigenetic 
silencing of the tumor suppressor gene induced by micro-duplication in two patients 
with familial early-onset CRC. From our results we conclude that CNV-associated 
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In order to identify novel genes involved in colorectal cancer (CRC) susceptibility, 
high-resolution SNP-based genomic profiling was carried out on germline DNAs of a 
carefully selected cohort of CRC patients. This led to the identification of several rare 
copy number variants (CNVs) affecting novel candidate CRC susceptibility loci, in­
cluding KIAA1797/miR-491. Previously, KIAA1797 has been associated with mitotic 
chromosome condensation and miR-491 has been found to play a role in sporadic 
CRC development. In order to establish their prevalence, we performed a locus-spe­
cific CNV screen in an additional cohort of 984 familial and/or early-onset CRC index 
patients. This screen yielded two novel CNVs encompassing the KIAA1797/miR- 
491 locus in two independent patients. No such variants were detected in a cohort 
of >3,400 non-affected individuals. From these results we conclude that recurrent 





Rare DNA copy number variants (CNVs) may impose serious effects on cancer sus­
ceptibility through e.g. loss or disruption of tumor suppressor and/or DNA repair 
genes (Kuiper et al., 2010). Well-known examples include the BRCA1 and BRCA2 
genes, the VHL gene, the APC gene, and a variety of mismatch repair genes (Wijnen 
et al., 1998, Wagner et al., Plaschke et al., 2003, Bunyan et al., 2004, Michils et al.,
2005). Rare CNVs may also target previously unknown genes in unexplained cancer 
families and, as such, may account for at least part of the so-called missing herit- 
ability gap (Manolio et al., 2009, Kuiper et al., 2010). In support of this notion, we re­
cently found that constitutional 3’ end EPCAM deletions can cause Lynch syndrome 
through epigenetic silencing by transcriptional read-through of the downstream mis­
match repair gene MSH2 (Ligtenberg et al., 2009, Kempers et al., 2011, Kuiper et al.,
2011). Furthermore, we have applied high-resolution DNA copy number profiling as 
an approach to discover novel predisposing genes in a stringently selected cohort of 
microsatellite stable colorectal cancer (CRC) families and early-onset CRC patients 
(Venkatachalam et al., 2011). One of the genes identified was PTPRJ (Venkatacha- 
lam et al., 2010b), a tumor suppressor gene previously denoted as a colon cancer 
susceptibility gene in mice (Ruivenkamp et al., 2002). Interestingly, we were able to 
show that also in this case epigenetic silencing resulted from transcriptional read- 
through (Venkatachalam, et al., 2010b).
In addition, we identified a novel candidate locus in CRC predisposition contain­
ing the hypothetical gene KIAA1797 and the microRNA (miRNA) gene miR-491 
(Venkatachalam et al., 2011). MiRNAs are regulatory non-coding RNAs, usually 21 
to 24 nucleotides in length, and are known to be involved in many cellular processes, 
including CRC development (Lu et al., 2005, Garzon et al., 2009). For example, 
miR-143 and miR-145 have been found to act as important players in the initiation of 
CRC, and chemically modified miR-143 has been suggested to serve as a candidate 
drug for the treatment of CRC (Akao et al., 2007, Kitade and Akao 2010). Addition­
ally, miRNA gene germline mutations and SNPs have been associated with cancer 
predisposition (Calin et al., 2005, Jazdezwski et al., 2008), and it has been shown 
that over-expression of miR-155 significantly down-regulates the mismatch repair 
(MMR) proteins MSH2, MSH6, and MLH1, thereby inducing a mutator phenotype 
and micro-satellite instability (MSI). Based on this latter finding, it has been proposed 
that constitutional miR-155 deregulation may cause Lynch syndrome in unexplained 
Lynch-like families (Valeri et al., 2010). Interestingly, miR-491 has been found to play 
a role in sporadic CRC development (Nakano et al., 2010), and the KIAA1797 gene 
has been associated with mitotic chromosome condensation (Matlik et al., 2006) 
Here, we have explored the relevance of the KIAA1797/miR-491 locus in CRC pre­
disposition in further detail through targeted DNA copy number screening in a large 
cohort of familial and/or early-onset CRC patients. By doing so, we found KIAA1797/ 
miR-491 to be recurrently affected in these patients, but not in >3,400 non-affected 




A cohort of 984 familial and/or early-onset microsatellite stable CRC index patients 
from the Netherlands, Germany and the UK was used in this study and has been 
described in chapter 2. In order to exclude common copy number polymorphisms, 
we compared the patient-derived data with CNVs reported in the Database of 
Genomic Variants (http://projects.tcag.ca/variation) (lafrate et al., 2004) and in our 
in-house database (>1600 controls, described in chapter 2). In addition, a control 
cohort consisting of 1880 healthy individuals (Nijmegen Biomedical Study) from 
the Netherlands was included, as well as 19 matched sporadic colon cancer and 
normal frozen tissue sample pairs. All patient and control material was obtained with 
informed consent.
Multiplex ligation-dependent probe amplification (MLPA) and genomic qPCR
To validate the initial SNP-based CNVs, and to screen additional cohorts of CRC 
patients and controls for these CNVs in a high-throughput mode, we performed 
multiplex ligation-dependent probe amplification (MLPA) as described in chapter
2. MLPA probes were designed for the KIAA1797/miR-491 locus according to 
guidelines provided by MRC-Holland (Amsterdam, The Netherlands). MLPA data 
were normalized and analyzed as explained in chapter 2. Genomic qPCR was 
performed through SYBR Green-based quantification (Bio-Rad, Veenendaal, the 
Netherlands) as described in chapter 2 . The genomic qPCR primers used are 
available upon request.
Sequence analysis
Genomic sequencing of the KIAA1797 gene was performed using standard 
procedures as reported in chapter 2. Mutation analysis of the data was carried out 
using the Vector NTI software package (Invitrogen).
qRT- PCR analysis
Real-time quantitative reverse transcription-PCR (qRT-PCR) was performed on a 
7500 Fast Real-Time PCR system (Applied Biosystems, Forster City, CA, USA) 
using SYBR Green-based quantification according to the manufacturer’s protocol 
(Bio-Rad, Veenendal, the Netherlands). cDNA was prepared from 2 ^g of RNA 
using reverse transcription kit RNA LA PCR kit (AMV) and the experiments were 
performed in duplicate. All qRT-PCR data were normalized using the house keeping 
gene GAPDH. Chi-squared test was employed to perform the statistical analysis and 




Recurrent KIAA1797/miR-491 deletions in familial and early-onset CRC pa­
tients
In our initial DNA copy number variant (CNV) screen of familial and early-onset mi­
crosatellite stable (MSS) colorectal cancer (CRC) patients, we identified an intra­
genic deletion affecting the KIAA1797 gene, including the miRNA miR-491, in one 
of the index patients (Venkatachalam et al., 2011) (Figure 1A). This patient, who 
had developed multiple adenomatous polyps (Table 1), was diagnosed with rectal 
carcinoma at the age of 33 years and was found to be wild-type for the APC gene 
(not shown). The index patient had several affected family members in both the pa­
ternal and maternal branches of the family but, besides the unaffected mother who 
carried the same germline deletion (not shown), no other samples were available 
for further analysis. Using genomic qPCR in conjunction with locus-specific primer 
pairs, we were able to fine-map this deletion and, found that it ranges from exons 4 
to 23 of the KIAA1797 gene. The deletion disrupts the open reading of the KIAA1797 
gene and also includes miRNA miR-491, which is positioned in intron 4 of the gene. 
CNVs affecting the KIAA1797/miR-491 locus were not reported before in public and/ 
or private databases of genomic variation. To explore the possibility that this locus is 
recurrently affected, we screened an additional cohort of 984 familial CRC patients, 
as well as 1880 healthy controls, using multiplex ligation-dependent probe amplifi­
cation (MLPA) analysis. Whereas no CNVs were found in the KIAA1797/miR-491 
locus of control individuals, two additional patients with distinct deletions affecting 
this locus were identified. One of these patients (Table 1, patient #2) was diagnosed 
with colorectal carcinoma at 62 years of age and, in addition, was found to have 
four relatives diagnosed with the same malignancy. By using a combined MLPA and 
genomic qPCR-based approach, we were able to establish that the deletion in this 
patient encompasses exons 2 to 14 of the KIAA1797 gene which, again, includes 
miR-491 (Figure 1). The second patient (Table 1, patient #3) was diagnosed with 
adenomas exhibiting mild to moderate dysplasia including polyps at 64 years of age. 
In this patient, we identified a deletion ranging from exons 7 to 20 of the KIAA1797 
gene (Figure 1). MiR-491 was not included in this latter deletion, which indicates that 
this miRNA is not targeted in this family. All three deletions appeared to be intragenic 
and affected the normal open reading frame, thus hampering the normal function of 
the KIAA1797 gene. Together, these data indicate that constitutional deletions in the 
KIAA1797/miR-491 locus are recurrently found in patients with colonic polyp forma­
tion and/or (early-onset) CRC development.
Lack of second-hit (somatic) mutations in the KIAA1797 gene
We assessed the tumor tissues of the index patients with deletions, wherever avail­
able, for the presence of somatic second-hit mutations using standard (Sanger) 
sequencing. In patient #2, harboring a deletion encompassing miR-491 and part 
of KIAA1797, no additional pathogenic KIAA1797 mutations were detected. From 
patient #3 we were able to obtain biopsies from three independent adenomas. The 
deletion in this patient encompassed only part of the KIAA1797 gene, excluding 
miR-491. Also here, no additional pathogenic KIAA1797 mutations were detected
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1 33 Rectal Carcinoma 4 4 to 23 Yes
2 62 Colorectal Carcinoma 4 2 to 14 Yes
3 64 Adenomatous polyps 3 7 to 20 No
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Figure 1. Recurrent deletions in KIAA1797/miR-491 locus (A) Structural organization of 
the KIAA1797/miR-491 locus, showing intragenic KIAA1797/miR-491 deletions in patient 
#1 (red bar), patient #2 (blue bar) and patient #3 (green bar). (B) Validation of the genomic 
deletion by MLPA in germline DNA of patient #1 (red line) and identification of genomic 
KIAA1797/miR-491 lesions by MLPA in the germline in patient #2 (blue line) and patient #3 
(green line). Black lines represent normal control DNAs. (ex: exon).
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Chapter 4
in either of the biopsies. The lack of overt second-hit mutations indicates that the 
observed KIAA1797 loss may result in haplo-insufficiency.
Elevated expression of KIAA1797 in sporadic colorectal tumors 
In order to substantiate the involvement of KIAA1797/miR-491 in CRC development 
we performed expression analyses of both KIAA1797 and miR-491 in a panel of 19 
matched normal colon and sporadic tumor tissues using qRT-PCR. We found that 
KIAA1797 exhibited a significantly higher expression in colon tumors as compared 
to the normal colon tissues (p = 0.0005) (Figure 2), whereas no significant changes 
in the expression of miR-491 were observed (data not shown). The elevated expres­
sion of KIAA1797 in colon tumors suggests that this gene does not function as a 
classical tumor suppressor gene, which typically show reduced expression in tumor 
tissues. This notion is in line with the absence of second-hit mutations in the tumor 
tissue of the index patients with KIAA1797 deletions.
Figure 2. Expression o f K1AA1797 gene in norm al co lon  and tu m o r tissues. Real­
time RT-PCR analysis of KIAA1797 in tumor and normal colon tissues. Expression values 
of KIAA1797 were normalized to the house-keeping gene GAPDH. Bars represent mean 
values of tumor and normal colon tissues (N- normal colon tissue and T- colon tumor 
tissue). Chi-squared test was used to calculate the p-value.
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We conclude that our DNA copy number screens have revealed KIAA1797/miR-491 
as a novel candidate CRC susceptibility locus. The occurrence of CNVs affecting 
this locus appears to be relatively rare (~0.3%) in early-onset or familial CRC cases, 
but was not detected in > 3,400 healthy individuals. The KIAA1797 gene encodes 
a predicted protein of 1801 amino acids long and includes a membrane-spanning 
domain. The function of the KIAA1797 protein is as yet ill-defined, although a role 
in mitotic chromosome condensation has been reported (Matlik et al., 2006). Also, 
homozygous KIAA1797 variants (SNP:g.chr9:20913668 G>A) have been found in 
sporadic breast cancer (Wood et al., 2007). Furthermore, frequent LOH and losses 
of chromosome 9p have been reported as common events in early-onset and spo­
radic CRCs, respectively (Weber et al., 1999, De Angelis et al., 1999), indicating 
that KIAA1797 may indeed play a significant role in tumor development. KIAA1797 
has been found to interact with vinucelin (VCL) (de Hoog et al., 2004), a cytoskel- 
etal protein associated with cell-cell and cell-matrix junctions involved in anchoring 
F-actin to the membrane (Hazan et al., 1997, Weiss et al., 1998). VCL is involved in 
cell surface E-cadherin expression by binding to beta-catenin (Peng et al., 2010) and 
has been found to regulate tumor suppressor PTEN protein levels by maintaining 
the interaction of the adherens junction protein p-catenin with the scaffolding protein 
MAGI-2 (Subauste et al., 2005). Therefore, being an interacting partner of VCL, 
KIAA1797 may play a role in cell-cell adhesion and, indirectly, Wnt signaling. Inter­
estingly, such a link with p-catenin-mediated cell-cell adhesion appears to exist also 
for two other candidate CRC susceptibility genes that we identified via our high-reso- 
lution SNP-based copy number profiling, i.e., PTPRJ and CDH18 (Venkatachalam et 
al., 2011), suggesting that this pathway may act as a common target. Together, these 
observations strongly suggest that KIAA1797 may play a role in CRC susceptibility 
and/or initiation. Interestingly, yet another independent KIAA1797 deletion was re­
cently encountered in a familial case of CRC (dr. S. Aretz, personal communication), 
further substantiating its role in CRC predisposition.
Deletions in miRNAs may be involved in cancer predisposition as well, as was pre­
viously shown by others (Calin et al., 2005, Jazdzewski et al., 2008). Despite the 
fact that miR-491 was not deleted in one of the three index patients, its role in CRC 
predisposition can as yet not be excluded, i.e., it is currently unclear whether the 
expression of the miR-491 allele that flanks the deletion in patient #3 is normal and/ 
or whether the observed loss of miR-491 in the two other patients affects the CRC 
risk. In fact, it has been shown that miR-491 can induce apoptosis by targeting Bcl- 
X(L) in CRC cells (Nakano et al., 2010). Moreover, in the human CRC cell line DLD- 
1, miR-491 markedly inhibited cell viability in vitro and its over expression inhibited 
tumor growth in vivo (Nakano et al., 2010). In addition, over-expression of miR-491 
was found to sensitize HepG2 cells for tumor necrosis factor-a-induced apoptosis 
(Yoon et al., 2010). It has also been demonstrated that miR-491-5p expression can 
be induced by TGF-p1 through the MEK/p38MAPK pathway, a well-known pathway 
involved in tumor development (Zhou et al., 2010). As such, miR-491 can be consid­
ered as a bona fide CRC predisposing gene. Although the exact involvement of miR- 




to be established, we conclude from our results that they may be more commonly 
affected by constitutional CNVs than previously thought and that they, as such, may 
play a role in CRC susceptibility.
In summary, our targeted screen for CNVs in large cohorts of CRC index patients 
and healthy controls, indicates that loss of the KIAA1797/miR-491 locus increases 
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Previously, using high-resolution genomic profiling on a stringently selected cohort of 
41 index patients, we detected two germline copy number variants (CNVs) affecting 
microRNA (miRNA) genes that could be involved in colorectal cancer (CRC) suscep­
tibility. Based on these observations, we hypothesized that germline CNVs affecting 
miRNA genes might prevalently affect CRC susceptibility. To test this hypothesis, we 
re-analyzed genomic copy number profiles from 69 young CRC patients and, indeed, 
found several private CNVs that were absent in the public database of genomic 
variants and our in-house database (>1600 unaffected controls). MiRNA genes are 
small in size and are, therefore, poorly covered by current human genome profiling 
platforms. To circumvent this problem, we newly designed a custom-made microar­
ray covering nearly 700 miRNA loci with ultra-high resolution. Using this microarray 
platform, we were able to detect several additional genomic copy number losses 
and gains affecting miRNA genes. To delineate the relevance of these CNVs in CRC 
susceptibility, and to explore their contribution to normal genome variation, we also 
analyzed CNV data from 994 healthy controls. Overall, we found 10% of the miRNA 
genes in the human genome to be affected by CNVs, of which 2% fulfils the criteria 
of a polymorphism. Our data indicate that whole genome miRNA copy number pro­
filing may provide novel insights into their role in health and disease, including the 





Colorectal cancer (CRC) syndromes are mostly caused by germline mutations in 
tumor suppressor genes or DNA repair genes (de la Chapelle, 2004). In spite of 
years of intense research, as yet only a few percent of the hereditary and/or familial 
CRC cases can be explained by mutations in either one of these genes (Aaltonen, 
2007). Previously, we set out to identify novel CRC predisposing genes using high­
resolution genomic profiling in a carefully selected cohort of 41 index patients. We 
detected, next to some interesting candidate genes, two microRNA (miRNA) genes, 
miR-491 and miR-646, that could be involved in CRC predisposition (Venkatacha- 
lam et al., 2011). MiRNAs are short, noncoding RNAs that regulate gene expres­
sion by sequence-specific base pairing in the 3’ or 5’ untranslated regions of tar­
get mRNAs, resulting in mRNA degradation or inhibition of translation (Di Leva and 
Croce, 2010). The expression of miRNAs is also tightly regulated and several of 
them appear to play important roles in the normal processes of cellular prolifera­
tion, differentiation and apoptosis (He and Hannon, 2004). Research during the last 
decade has also shown that several miRNAs may be implicated in the etiology and 
progression of cancer, and miRNA expression profiles have been uniquely linked to 
various cancer types and subtypes (Di Leva and Croce, 2010). Whereas most can­
cer (sub)types show an overall down-regulation of miRNAs (Lu et al., 2005), specific 
miRNAs have been found to be either up- or down-regulated in certain cancer (sub) 
types, the archetypical examples of which are miR-21 and Let-7, which were found 
to have oncogenic and tumor suppressive functions, respectively (Chen, 2005, Vo- 
linia et al., 2006, Ryan et al., 2010). Other examples include miR-143, miR-145, 
miR-17-5p, miR-20a, miR-92, miR-106a, and miR-155, which have been implicated 
in the pathogenesis of colon, lung, breast, stomach, prostate, and pancreatic can­
cers, respectively (Volinia et al., 2006, Kitade and Akao, 2010). Moreover, germline 
mutations and SNPs in miRNAs have been suggested to be involved in cancer pre­
disposition (Calin et al., 2005, Jazdzewski et al., 2008). Based on our own data, we 
have recently proposed that genomic copy number variants (CNVs) affecting miRNA 
genes may result in moderate- to high-penetrance forms of disease predisposition, 
including CRC (Venkatachalam et al., 2011). As yet, however, little is known about 
the role of miRNA CNVs in cancer predisposition. Here, we assessed the occurrence 
and frequency of miRNA CNVs in a cohort of early-onset familial CRC patients and 
a matched cohort of unaffected controls. From our results we conclude (i) that com­
mon CNVs (polymorphisms) may include miRNAs and (ii) that rare CNVs encom­
passing miRNAs may affect CRC susceptibility.
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Materials and Methods
Patient and control material
We included in our study 69 microsatellite-stable (MSS) colorectal cancer (CRC) 
patients under the suspicion for hereditary or familial CRC because they were (i) 
diagnosed at or below the age of 40, (ii) diagnosed below the age of 50 with at least 
two first-degree relatives with CRC, (iii) diagnosed below the age of 50 with an ap­
parent recessive inheritance pattern (i.e., a horizontal transmission pattern: multiple 
affected siblings from unaffected parents), or (iv) diagnosed below the age of 60 with 
at least three first-degree relatives with CRC. For ultra-high resolution copy number 
profiling using a custom-designed miRNA microarray (see below) we included 17 
MSS CRC patients below 40 years of age. A cohort of healthy controls was deduced 
from the Nijmegen Brain Imaging Genetics (BIG) study, and entails DNA isolated 
from peripheral blood of healthy Nijmegen students. All patient and control material 
was obtained with informed consent.
SNP-based array CGH and copy number analysis
Genomic DNA extracted from peripheral blood cells of 69 CRC index patients was 
hybridized on single nucleotide polymorphism (SNP) 250 k (32 patients) or SNP 6.0 
(37 patients) Affymertix GeneChip arrays, according to standard protocols provided 
by the manufacturer (Gene Chip Mapping 500K and 6.0 Assay manual). The subse­
quent genomic copy number analyses were performed essentially as described in 
chapter 2.
Ultra-high-resolution array CGH
For ultra high resolution genomic copy number variant (CNV) analyses, we newly 
designed an oligonucleotide microarray (Roche NimbleGen Systems, Madison, WI, 
USA) consisting of 385,000 probes encompassing 695 annotated miRNA genes. 
The microarray has a tiling resolution (1 probe every 10 base pairs) covering the 
miRNAs and a high density resolution (1 probe every 50 base pairs) around the 
miRNAs, thus allowing the detection of small (<1kb) lesions (Figure 1). Microarray 
hybridization, post-hybridization, wash and scanning steps were performed accord­
ing to the manufacturer’s instructions (Roche NimbleGen Systems). DNA extracted 
from peripheral blood cells of early-onset CRC patients and normal controls was 
hybridized to the microarrays and the images were acquired and analyzed using 
NimbleScan V2.4 extraction software (Roche NimbleGen Systems). The SegMNT 
algorithm was used to calculate log2(Cy3/Cy5) ratios or log2(Cy5/Cy3) ratios for 
each probe on the microarray. CNV analysis was performed using Nexus software 
and log2 ratio’s of > 0.18 were scored as gains and < -0.18 as losses, respectively.
Multiplex ligation-dependent probe amplification (MLPA)
Multiplex ligation-dependent probe amplification (MLPA) was employed to validate 
the CNVs detected by our custom-designed miRNA microarray. The MLPA technique 
was performed, and its data were analysed, essentially as explained in chapter 2.
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Chapter 5
Genomic real-time quantitative PCR
Genomic real-time quantitative PCR (qPCR) was employed to validate the miRNA 
CNVs detected by our custom-designed miRNA microarray. The qPCR technique 
was performed, and its data were analysed, essentially as described in chapter 2.
Figure 1: Ultra-high-resolution custom-designed miRNA microarray allowing the 
detection small (<1kb) miRNA lesions. The miRNA microarray encompasses genomic 
regions with tiling resolution of 1 probe per every 10 base pairs covering the miRNAs (white 
box). In addition, the miRNA microarray encompasses genomic regions with a resolution of 
1 probe per every 50 base pairs bracketing the miRNAs (grey region).
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Results
Novel germline CNVs affecting miRNA genes in CRC patients
Based on our previous results we hypothesized that, in addition to the candidate 
miRNA genes that we identified before (Venkatachalam et al., 2011), other miRNA 
genes might be targeted by germline CNVs in early-onset and/or familial CRC 
patients. To test this hypothesis, we re-analysed genomic copy number data from 69 
young CRC patients obtained by using the Affymetrix 250k and SNP6.0 microarray 
platforms, respectively. Indeed, we identified several CNVs encompassing miRNAs 
that were not noted before, due to their recent annotation. Some of the miRNA 
genes were affected by recurrent CNVs (frequency >1%). These CNVs most likely 
represent neutral copy number polymorphisms. Furthermore, besides miR-491 and 
miR-646, we detected 3 distinct miRNAs that were affected by losses and gains in 
the germline of young CRC patients (Table 1). None of these miRNA genes were 
found to be affected by harmless genomic copy number variations as reported in 
the Database of Genomic Variants (http://projects.tcag.ca/variation/) (Iafrate et al., 
2004) and in our in-house database (>1600 unaffected controls). Thus re-analysis of 
our existing CNV data has yielded interesting novel miRNA genes that could play a 
role in CRC susceptibility.
Novel germline CNVs affecting miRNA genes by targeted analysis
MiRNAs are small in size (approximately 100 bps), hence CNVs affecting miRNAs 
could easily be missed by the microarray platforms currently used, which usually 
have a resolution of 5-10 kb. Consequently, we designed a miRNA oligonucleotide 
microarray containing 385,000 probes encompassing all 695 annotated miRNA 
genes (known at the time of design). The array has a high local probe density within 
(tiling resolution) and around (high density resolution) miRNA genes in order to 
increase the chance of detecting small (<1kb) lesions (see material and methods) 
(Figure 1). To the best of our knowledge this microarray is the first of its kind capable 
of detecting small sized CNVs targeting miRNA genes. As a proof of principle, we 
hybridized a small cohort of patients with unexplained Lynch syndrome-like clinical 
characteristics to the microarray and found a 300 bp high-level amplification affecting 
miR-646 that could subsequently be validated by MLPA (Figure 2). Interestingly, this 
miRNA was previously found to be deleted in a patient diagnosed with CRC at 36 
years with rectum carcinoma (Venkatachalam et al., 2011). The exact impact of this 
miR-646 amplification on the Lynch-like phenotype is as yet, however, unclear since 
also a 3’ germline deletion in the EPCAM  gene was found in this family (Ligtenberg 
et al., 2009). Despite the fact that the miR-646 amplification was only found in one 
of the affected members in the family (i.e., de novo CNV), a putative role as modifier 
(Nadeau et al., 2001) in this particular patient can, as yet, not be excluded.
Using this new custom-designed miRNA microarray we subsequently performed a 
genomic copy number screen in a cohort of 17 CRC patients with an early age 
of onset (<40 years). Several germline DNA copy number gains and losses were 
detected in these patients, most of which were uniquely and recurrently affected in 
our CRC cohort, such as for example miR-570. Attempts to validate these lesions 
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Figure 2: Array CGH profiling of germline DNA of a CRC patient using a custom- 
designed miRNA microarray and its validation. (A) Copy number plot of a chromosomal 
segment depicting the targeted coverage of 17 miRNAs within this region, of which miR- 
646 shows amplification (arrow). (B) Zoom-in of the region around miR-646, showing 
amplification (300 bp region) within an intron of a hypothetical gene. (C) Validation of the 
300 bp genomic amplification by MLPA in DNA of the CRC patient (grey line). The black 
coloured lines represent normal control DNAs.
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so far unsuccessful, probably due to local genomic architectural features and/or 
the occurrence of repetitive sequences within the genomic regions involved. One 
exception was a unique deletion affecting miR-770, detected in one of our index 
MSS CRC patients, which we were able to validate by genomic qPCR (data not 
shown).
Copy number polymorphisms affecting miRNA genes
In order to ascertain the impact of the miRNA CNVs in human CRC susceptibility it 
is imperative to first catalog the genomic CNVs affecting miRNA genes in healthy 
individuals. As of yet, such information is not available. Therefore, we analyzed CNVs 
affecting miRNAs as detected in peripheral blood-derived DNA of 994 young healthy 
individuals from Nijmegen (BIG cohort) who were hybridized to a SNP 6.0 microarray 
(Franke et al., 2010). In total, we found 94 out of 1049 (9.5%) annotated miRNAs 
(miRBase, Sep 2010 release) to be affected by CNVs at least once, and 20 miRNA 
genes (1.9%) with a frequency of >1% (i.e., copy number polymorphisms; Table 2). 
In comparison, we found 609 protein coding genes out of a total of 20853 (2.9%) to 
be affected by common copy number polymorphisms in this control cohort. Thus, 
miRNA genes appear to be less frequently affected by normal copy number variation 
as compared to protein coding genes. Most of the miRNA genes affected by normal 
CNVs in our healthy control cohort were just recently annotated and, hence, detailed 
information about their function is still pending. We also detected miR-570 (see 
above) to be affected with a frequency of 18% in our cohort of healthy individuals. 
So, CNVs affecting miR-570 occur as common copy number polymorphisms and, 
therefore, most likely play no significant role in CRC susceptibility.
Table 1: Unique miRNA CNVs in exclusively detected CRC patients using SNP arrays
MiRNA genes Cytoband CNV Occurence 
(69 CRC samples)1
miR-491 9p21.3 Loss 1
miR-646 20q13.33 Loss 1
miR-335 7q32.2 Loss 1
miR-29c; miR-29b-2 1q32.2 Loss 1
miR-3132 2q35 Gain 1
1Occurence of the miRNA genes CNVs in 69 CRC samples and not in 994 young healthy 
individuals.
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Table 2: Recurrent (>1%) common genomic copy number polymorphisms affecting miRNAs O
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miR-3118-4 19,302 15q 11.2 222 244 - 8 48
miR-1268 20,014 15q 11.2 245 213 - 12 47
miR-3675 17,058 1 p36.13 128 170 - 1 30
miR-1302-2 20 1 p36.33 89 83 3 10 19
miR-570 196,91 3q29 79 95 2 1 18
miR-3118-6 19,302 15q 11.2 59 103 - 1 16
miR-1233-2 32,607 15q14 5 126 7 - 14
miR-3713 74,666 15q24.3 52 5 2 11 7
miR-3180-1 14,912 16p13.11 12 46 - - 6
miR-3179-1 14,902 16p13.11 12 46 - - 6
miR-3670 14,909 16p13.11 17 48 - - 6
miR-1299 68,292 9q12 10 33 - - 4
miR-1972-1 15,011 16p13.11 6 31 - - 4
miR-1302-10 100,32 15q26.3 7 15 - 2 2
miR-3680 21,424 16p12.2 3 20 - - 2
miR-548i-3 7,983 8p23.1 9 9 - - 2
miR-548x 18,98 21q21.1 16 - - - 2
miR-1233-1 32,461 15q14 0 15 - - 2
miR-1324 75,762 3p12.3 3 9 - - 1
miR-3910-1 93,438 9q22.31 0 10 - - 1
miR-3910-2 93,438 9q22.31 0 10 - - 1
Our results indicate that miRNAs are recurrently affected by CNVs, as part of normal 
genomic variation, but potentially also as part of disease-causing genomic varia­
tion. Previously, using high resolution genomic profiling, we reported two candidate 
germline miRNA CNVs to be involved in CRC susceptibility (Venkatachalam et al., 
2011). In order to detect other germline miRNA CNVs that could be involved in CRC 
development and/or susceptibility, we re-analysed genomic copy number data from 
69 young CRC patients. Interestingly, this re-analysis revealed 3 distinct germline 
miRNA CNVs that were not encountered as common copy number polymorphisms 
before, suggesting a possible role in CRC susceptibility. The exact role of these 
miRNA CNVs in CRC predisposition, however, awaits the in-depth assessment of 
larger patient-control cohorts.
To explore whether miRNAs could also be targeted by small (<5kb) CNVs, we per­
formed an additional copy number screen using a new targeted custom-designed 
miRNA microarray and, found several focal germline miRNA deletions and duplica­
tions. Thus far, however, we were unable to confirm most of these miRNA CNVs by 
independent methods, possibly due to local genomic architectural and/or sequence- 
specific features. These problems may be circumvented in the future by improving 
the microarray design through e.g. the selection and extension of genomic regions 
just outside the miRNA genes. Furthermore, it is anticipated that the increasing 
probe density of new genome-wide microarray platforms, as well as the rapid im­
plementation of next generation sequencing approaches, will facilitate the efficient 
detection of CNVs and/or mutations affecting miRNA genes. Nonetheless, using our 
custom-designed miRNA microarray, we were able to identify unique CNVs affecting 
miR-646 and miR-770, 300 bps and ~1200 bps in size, respectively, which could be 
validated by other methods, thereby underscoring the assumption that small miRNA 
CNVs do occur.
To ascertain the role of these miRNAs in disease susceptibility, we screened a large 
cohort (994 individuals) of healthy controls. Through this genome wide copy number 
screen we focused on 1049 miRNA genes and found that 20 of these genes were 
located in regions that were polymorphic in more than 5% of the individuals. In ad­
dition, a considerable number of miRNA genes (i.e., 47 miRNAs in controls) was af­
fected by CNVs in single individuals. We found 1,9% of the miRNAs to be affected by 
common copy number polymorphisms, several of which were also found to be recur­
rently affected in our CRC cohort. These findings suggest that these miRNA genes 
may, similar to protein coding genes, play a role in overall phenotypic diversity and 
may be less relevant to CRC susceptibility and/or development. Most of the miRNAs 
located within polymorphic CNVs, however, were only recently annotated and their 
role (and/or that of their targets) in cancer development is still largely unexplored. 
Since common copy number polymorphisms do occur in miRNA genes we propose 
that, analogous to SNPs, CNVs in miRNAs can be exploited in genome-wide asso­
ciation studies to assess cancer risk as well.
Different types of genetic variability affecting miRNA function can be distinguished. 
For instance, miRNAs can regulate gene expression by sequence-specific base 




iations or mutations in 3’UTRs may result in a specific deregulation of that particular 
target. Indeed, polymorphisms in 3’ UTR miRNA binding sites were previously found 
to be associated with CRC risk (Landi et al., 2008). Interestingly, SNPs or genetic 
variants in the miR-125b binding sites of the BMPR1B 3’UTR, the let-7 miRNA com­
plementary site in the 3’ UTR of KRAS and the miR-221 complementary site in the 
KIT  3’ UTR, have been found to confer an increased risk to breast cancer, non-small 
cell lung cancer and ovarian cancer, and acral melanoma, respectively (Saetrom et 
al.,2009, Chin et al., 2008, Ratner et al., 2010, Godshalk et al., 2010). It has also 
been shown that 3’UTR shortening or polymorphisms can prevent miRNA binding to 
their mRNA targets (Polisen et al., 2010). Variations or mutations in mature miRNA 
sequence themselves can be expected to have much broader consequences, since 
they may lead to a change in the entire spectrum of target genes due to increased 
affinity for some targets and decreased affinity for others. Also, SNPs affecting miR- 
NAs have been associated with inborn cancer susceptibility. For example, a SNP in 
pre-miR-146a has been found to play a role in the genetic predisposition to papillary 
thyroid carcinoma, mediated by target genes of which the expression is affected by 
the SNP status (Jazdzewski et al., 2008). Finally, variation in the expression levels 
of miRNAs, including miRNAs identified in this study, is expected to affect the entire 
spectrum of target genes in a dose-dependent manner, leading to deregulation of 
various cellular signaling pathways. Over-expression of miR-155 results in pleio- 
typic effects by causing down-modulation of the core mismatch repair heterodimeric 
proteins MSH2-MSH6 and MLH1-PMS2 (Valeri et al., 2010). Previously, a germline 
mutation in the miR16-1/miR-15a precursor was shown to result in its decreased ex­
pression and, consequently, an increased risk to develop chronic lymphocytic leuke­
mia (Calin et al., 2005). We expect that CNVs disrupting miRNAs may have a similar 
effect on CRC risk, either by decreased or increased expression.
In summary, we conclude that a subset of germline CNVs encompassing miRNAs 
may occur as harmless polymorphisms, whereas others may underlie cancer sus­
ceptibility. Further detailed analyses using alternative methods and/or platforms are 
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Recently, we identified 3’ end deletions in the EPCAM gene as a novel cause of 
Lynch syndrome. These truncating EPCAM deletions cause allele-specific epigenetic 
silencing of the neighboring DNA mismatch repair gene MSH2 in tissues expressing 
EPCAM. Here we screened a cohort of unexplained Lynch-like families for the 
presence of EPCAM deletions. We identified 27 novel independent MSH2-deficient 
families from multiple geographical origins with varying deletions all encompassing 
the 3’ end of EPCAM, but leaving the MSH2 gene intact. Within the Netherlands and 
Germany, EPCAM deletions appeared to represent at least 2.8% and 1.1% of the 
confirmed Lynch syndrome families, respectively. MSH2 promoter methylation was 
observed in epithelial tissues of all deletion carriers tested, thus confirming silencing 
of MSH2 as the causative defect. In a total of 45 families, 19 different deletions were 
found, all including the last two exons and the transcription termination signal of 
EPCAM. All deletions appeared to originate from Alu-repeat mediated recombination 
events. In 17 cases regions of microhomology around the breakpoints were found, 
suggesting non-allelic homologous recombination as the most likely mechanism. 
We conclude that 3’ end EPCAM deletions are a recurrent cause of Lynch syndrome 





The most frequently diagnosed colorectal cancer (CRC) syndrome is Lynch 
syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC) 
(MIMs 120435, 609310), which accounts for up to 5% of CRCs. Mutation carriers 
exhibit a high risk to develop CRC (60-90%), endometrial cancer (20-60%), as well 
as several other cancers (Lynch and de la Chapelle, 2003, Watson et al., 2008). 
Lynch syndrome is caused by a germline mutation in one of the DNA mismatch 
repair (MMR) genes MSH2, MLH1, MSH6 or PMS2 (Aaltonen et al., 1998, Lynch 
and de la Chapelle, 2003, Hampel et al., 2005, Barnetson et al., 2006) (MIM 120436, 
609309, 600678, 600259). MSH2 and MLH1 account for the majority of the identified 
mutations, whereas PMS2 mutations explain only a few percent of the confirmed 
cases (Lynch and de la Chapelle, 2003, Barnetson et al., 2006).
Increasing evidence suggests that also epigenetic modifications may play a role 
in cancer predisposition in Lynch syndrome. Several groups have reported the 
occurrence of mono-allelic methylation of the MLH1 gene promoter in peripheral 
blood cells of individuals that meet the criteria for Lynch syndrome, but lack germline 
mutations in the MLH1 gene (Gazzoli et al., 2002, Suter et al., 2004, Hitchins et 
al., 2007). Occasionally, these so-called epimutations were found to be transmitted 
over several generations, but the mechanism underlying this phenomenon 
remains to be elucidated (Hitchins et al., 2007, Morak et al., 2008, Hesson et al., 
2010). Chan et al. (2006) for the first time reported an inherited germline MSH2 
epimutation in a family presenting with Lynch-associated tumors and a mosaic 
MSH2 hypermethylation pattern in normal tissues. Recently, we demonstrated that 
these families carry 3’ end deletions in the epithelial cell adhesion molecule gene 
EPCAM (MIM 185535), previously known as TACSTD1, which is located upstream 
of the MSH2 gene. EPCAM is highly expressed in epithelial tissues and carcinomas 
(Winter et al., 2003), and these deletions were found to result in transcriptional read- 
through into the MSH2 gene and subsequent hypermethylation of its CpG island 
promoter in EPCAM-expressing tissues (Ligtenberg et al., 2009), thereby providing 
an explanation for the origin of the epimutation and its mode of inheritance. The 
identification of several additional families with 3’ EPCAM deletions by others (van 
der Klift et al., 2005, Kovacs et al., 2009, Niessen et al., 2009, Nagasaka et al., 2010, 
Guarinos et al., 2010) has underscored the notion that these abnormalities indeed 
represent a common cause of Lynch syndrome.
Here, we report the characterization of EPCAM deletions in 45 independent Lynch 
syndrome families, including hypermethylation of the MSH2 gene promoter. The 
incidence of EPCAM deletions appeared to vary between populations and was 
found to represent at least 1-3% of the explained Lynch syndrome families. Detailed 





A total of 27 families with EPCAM deletions originating from The Netherlands (n=10), 
Germany (n=11), USA (n=4), UK (n=1), and Canada (n=1) were identified through 
targeted genomic screens in cohorts of unexplained Lynch-like families, using 
variable inclusion criteria, i.e., unexplained patients with MSH2-deficient and/or 
microsatellite-instable tumors. In addition, 18 EPCAM deletion families of various 
origins from earlier studies were included in the breakpoint analyses. All patient 
material was obtained with informed consent.
Multiplex ligation-dependent probe amplification (MLPA)
EPCAM deletion screening was performed with MLPA using SALSA MLPA kits 
P072-B1 MSH6 or P008 MSH2/PMS2 (MRC-Holland, Amsterdam, The Netherlands). 
For fine-mapping of the identified deletions we used two custom-designed probe 
sets as previously described (Ligtenberg et al., 2009), in which two additional probes 
targeting the EPCAM promoter region (probe O) and intron 4 of the EPCAM gene 
(probe P) were included (Figure 1). Primers were designed using the MeltIngeny 
program according to guidelines provided by MRC-Holland and are available upon 
request.
Long range PCR and breakpoint sequencing
Based on the MLPA results, long range PCR across the deletion was applied using 
a TAKARA LA PCR kit (TaKaRa Bio Inc., Otsu, Shiga, Japan) or the Expand Long 
Range kit (deletions 8, 9, 13, and 14; Roche Applied Sciences, Mannheim, Germany). 
To identify the exact breakpoints, the PCR products were directly sequenced at 
various positions in both orientations. Primers used for these analyses are available 
upon request.
Methylation analysis
Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) 
analyses were performed using SALSA MS-MLPA kit ME011 Mismatch Repair 
genes (MMR) (MRC-Holland) as previously described (Ligtenberg et al., 2009), 
using 200 ng DNA isolated from formalin fixed paraffin embedded material. Samples 
with known MGMT, MLH1 or MSH2 hypermethylation levels were used as positive 
controls.
Bioinformatic analysis of SINE density
The density of short interspersed nuclear elements (SINEs), which include Alu 
repeats, in the maximal deletion region was compared to the remainder of the 
genome by random sampling of 10,000 genomic sequences of 25 kb in size. These 
sequences were obtained from hg18 (http://genome.ucsc.edu/) by random selection 
of autosomal chromosomes and subsequent locations. Centromeres and gaps in 
the sequence alignment were excluded. These 25 kb regions were annotated for 
the presence of all repeat masked elements, and the number of SINE elements was
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calculated. Next, the 95% confidence interval for the presence of SINEs within these 
10,000 genomic regions was determined.
Table 1. Relative incidence of EPCAM deletions in The Netherlands and Germany
Cohort no. of 
families
% of explained 
MSH2-deficient 
fam ilies5
% of explained 
Lynch families
The Netherlands1
EPCAM deletions3 17 6.9% 2.8%
EPCAM founder deletions3 16 6.5% 2.6%
MSH2 mutations4 230 37.2%
Explained Lynch families 618
Germany2
EPCAM deletions 11 2.3% 1.1%
MSH2 mutations4 458 47.9%
Explained Lynch families 957
1Includes all unique families that are known in one of the DNA diagnostic laboratories in 
Nijmegen, Rotterdam, Leiden, Amsterdam (Netherlands Cancer Institute, University of 
Amsterdam, and the Free University of Amsterdam), Utrecht, and Groningen. 2Includes all 
unique families that are known by the German HNPCC consortium. 3All cases known thus 
far are reported in this study. 4Including MSH2 deletions and EPCAM-MSH2 deletions. 
5The total number of families with MSH2-deficient tumors is composed of families carrying 
MSH2 mutations or deletions and EPCAM deletions.
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Results
Identification o f novel EPCAM  deletions in MSH2-deficient Lynch families
In a search for novel germline EPCAM deletion cases we performed a multicenter 
screen of unexplained Lynch-like families using multiplex ligation-dependent probe 
amplification (MLPA) and/or deletion PCR, which yielded 27 novel EPCAM deletion 
families. Through the participation of all clinical genetic centers in The Netherlands, 
we have now identified 17 unrelated Dutch families with EPCAM deletions, thus 
representing 2.8% of all explained Lynch syndrome families and 6.9% of all explained 
MSH2-deficient families in this country, respectively (Table 1). Additionally, 11 German 
EPCAM deletion families were found in a systematic screen of 146 families with 
MSH2-deficient tumors in which no MSH2 mutations were found (7.5%). Therefore, 
in Germany the frequency of EPCAM deletion families in explained Lynch families 
is at least 1.1%, which is 2.3% of all explained MSH2-deficient families. (Table 1).
In addition to these 27 families, we included 18 EPCAM  deletion families that 
were previously reported by us and others. Together, these screens and searches 
resulted in 45 independent families with EPCAM deletions originating from eight 
different countries. Using long-range PCR we precisely localized and sequenced the 
breakpoints in all EPCAM deletion families (Table 2). In total, 19 different deletions 
were identified, varying in size from 2.6 to 23.8 kb. All deletions were located 
upstream of the MSH2 gene promoter and encompassed at least the last two exons 
of the EPCAM gene, leaving its 5’ exons intact (Figure 1A). Our breakpoint mapping 
data indicate that a wide variety of EPCAM  deletions does occur in these Lynch 
syndrome families.
EPCAM  deletion carriers show MSH2 promoter hypermethylation
We previously showed for two different deletions (deletions 1 and 5, Table 2) that 
they result in allele-specific hypermethylation of the MSH2 gene promoter in tissues 
expressing EPCAM (Ligtenberg et al., 2009). Here, we analyzed the methylation 
status of the MSH2 gene promoter in tumor and/or normal colon mucosa tissues of at 
least one index patient from each of 27 different families (encompassing 11 different 
deletions) using methylation-specific multiplex ligation-dependent probe amplification 
(MS-MLPA, Table 2). MSH2 promoter hypermethylation was detected in all tissues 
tested. One of the patients in our cohort also developed a benign dermatofibroma, 
which was not MSH2-deficient and, in contrast to the colorectal tumor, indeed was 
found to lack hypermethylation of the MSH2 gene promoter. Therefore, we conclude 
that hypermethylation of the MSH2 gene promoter in tissues expressing EPCAM is 
a general phenomenon in the deletion carriers, thereby explaining the concomitant 
cancer predisposition in these families.
EPCAM  founder deletions
Several EPCAM  deletions appeared to be widespread both within and between 
different populations. The 4.9-kb EPCAM founder deletion, thus far observed in 
seven Dutch families (Ligtenberg et al., 2009, Niessen et al., 2009), was found to 
be present in nine out of ten additional families from The Netherlands, but in none 
of the families from other geographic origins, thus confirming its founder nature.
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Figure 1. EPCAM de le tions in Lynch syndrom e patients. (A): Schematic outline of the 
genomic region around EPCAM and MSH2, showing 19 different deletions (grey bars) 
identified in 45 families. All deletions include at least exons 8 and 9 of EPCAM. Deletions 
identified in multiple (apparently) unrelated families are indicated in dark grey. Positions 
of the MLPA probes used for deletion mapping are indicated by triangles. All intragenic 
(B) and intergenic (C) breakpoints are located in Alu repeats (referred to as SINEs: short 
interspersed nuclear elements, red bars), of which eight are involved in several different 
deletions (indicated by arrows and numbers of the deletion). Arrowheads above the bars 
denote the orientation of the repeats.
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Furthermore, this founder deletion appears to represent a considerable fraction 
(~6.5%) of the explained MSH2-deficient Lynch syndrome families in this population 
(Table 1). In addition, six EPCAM deletions were identified in more than one 
family originating from Germany (deletions 2 and 14, n=2 and n=4, respectively), 
Switzerland (deletion 3, n=2), and the USA (deletion 6, n=2) or from multiple origins 
(deletions 5 and 10, n=3; Table 2). Although we cannot rule out with certainty that 
these deletions have occurred independently, we anticipate that most of them will 
have an ancestral origin.
A/u-mediated recombination as a mechanism o f origin
It is well-established now that repetitive DNA sequences, such as Alu repeats, can 
act as facilitators of chromosomal rearrangements (Stankiewicz and Lupski 2010). 
Previous reports have already suggested Alu repeat-mediated recombination as 
a likely mechanism for some of the EPCAM deletions (van der Klift et al., 2005, 
Kovacs et al., 2009, Ligtenberg et al., 2009). Indeed, all EPCAM  deletion breakpoints 
characterized in this study were located within Alu elements (Table 2 and Figure 1). 
Together, the 19 different deletions involved 11 Alu repeats at the distal intragenic 
breakpoints (within EPCAM), and 13 at the proximal breakpoints (in the intergenic 
region between EPCAM and MSH2), of which several were involved in different 
deletions (Figure 1B and 1C). As expected, the two recombined Alu elements were 
always directed in the same orientation, being either sense (deletions 5-11) or 
antisense (deletions 1-4 and 12-19). For 17/19 (89%) of the deletions, sequence 
alignment of the distal and proximal Alu repeats revealed the presence of stretches 
with microhomology at the breakpoint, ranging from 6 to 32 bp in size (Table 2), 
which is in line with Alu-Alu mediated non-allelic homologous recombination (NAHR). 
Interestingly, two deletions of exactly the same size (deletions 7 and 8) appeared 
to originate from recombination events at different positions within the same Alu 
repeat pair with high sequence homology, further illustrating the homology-based 
mechanism driving these genomic deletions (Figure 2).
The remaining two deletions (9 and 12) appear to have arisen by a mechanism different 
from NAHR. Deletion 9, of which the breakpoints are near those of deletions 7 and 8 
(Table 1), contains a 2-nt interstitial sequence (AG) and lacks microhomology at the 
breakpoint junction. Similarly, the sequences surrounding the breakpoint junctions 
of deletion 12 do, with only 3 bases, not contain sufficient homology in order to be 
explained by NAHR. In these cases, classical non-homologous end-joining (NHEJ) 
or microhomology-mediated break-induced repair (MMBIR) may serve as better 
explanations for the origin of the deletion (McVety et al., 2005, Vissers et al., 2009). 
Partial or complete deletion of the MSH2 gene represents a relatively frequent cause 
of Lynch syndrome (van der Klift et al., 2005, Li et al., 2006). These germline deletions 
appear to originate almost exclusively from Alu-mediated recombination, which is in 
accordance with the relatively high local density of repetitive Alu elements (Li et 
al., 2006). We have extended this analysis by determining the relative Alu element 
density throughout the entire EPCAM-MSH2 locus in a genome-wide context. To 
this end, we randomly sampled 10,000 genomic regions of 25 kb. This yielded a 
median Alu element density of 10 (95%CI: 0-39), which is significantly lower than the 
density of 55 Alu elements that we observed within the 25-kb EPCAM-MSH2 locus.
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1 NL 16 8+9 4,909 c.859-1462_*1999del 6 bp
2 D 2 5-9 11,660 c.491+529_*874del 25 bp
3 CH 2 5-9 23,829 c.492-509_*13721del 24 bp
4 H 1 6-9 10,355 c.555+402_*1220del 12 bp
5 CN/USA 3 6-9 22,836 c.555+927_*14226del 32 bp
6 USA 2 6-9 13,128 c.555+901_*4492del 15 bp
7 NL 1 8+9 9.963 c.858+1244_*4562del 18 bp
8 D 1 8+9 9,963 c.858+1211_4529del 8 bp
9 D 1 8+9 10,074 c.858+1364_*4793del_insAG -
10 D/H 8+9 8,674 c.858+2478_*4507del 14 bp
11 H 1 8+9 14,734 c.859-2524_*10762del 15 bp
12 UK 1 8+9 2,419 c.859-353_*618del 3 bp
13 D 1 8+9 2,648 c.859-670_*530del 18 bp
14 D3 8+9 16,834 c.859-689_*14697del 24 bp
15 H 1 8+9 6,058 c.859-696_*3914del 19 bp
16 D 1 8+9 5,246 c.859-1682_*2116del 13 bp
17 USA 1 8+9 8,879 c.859-1605_*5862del 10 bp
18 USA 1 8+9 13,004 c.859-645_*10911del 14 bp
19 D 1 4-9 16,500 c.423-545_*3903del 7 bp
1Families originate from The Netherlands (NL), Germany (D), Switzerland, (CH), Hungary
(H), China (CN), USA, and UK. 2Nomenclature is based on mRNA sequence with Genebank 















AluSx AluSq 84% for 211/250 yes (12) Ligtenberg et al, 2009; 
Niessen et al., 2009
AluSg AluSg/x 78% for 156/198 yes (1)
AluSp AluSg 79% for 232/292 yes (1) Van der Klift et al., 2005
AluSx AluSx 77% for 241/309 NA Kovacs et al., 2009
AluY AluSc 79% for 237/300 yes (2) Ligtenberg et al., 2009
AluY AluSx 79% for 225/282 yes (2)
AluSp AluSx 85% for 243/284 NA
AluSp AluSx 82% for 240/291 yes (1)
AluSp FLAM-C Alu 85% for 243/284 yes (1)
AluSp AluSx 83% for 232/278 NA Kovacs et al., 2009
AluSp AluSp 86% for 137/159 NA
AluSx AluSg 78% for 222/282 yes (1)
AluSx AluSg 78% for 246/312 yes (1)
AluSx AluSx 82% for 246/299 yes(4)
AluSx AluJo 75% for 114/151 NA Kovacs et al., 2009
AluJb AluSq 78% for 180/229 NA
AluJb AluSq 79% for 153/193 yes (1)
AluSx AluSx 91% for 73/80 NA Van der Klift et al., 2005
AluSq AluJo 80% for 183/227 NA
3Includes one family from unknown European origin [van der Klift et al., 2005]. 4Alu-
subfamily identified at each each breakpoint [Batzer and Deininger, 2002]. 5Methylation
specific-MLPA on normal colon mucosa and/or colorectal tumor tissues.
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This local enrichment is also observed in other regions with recurrent A/u-mediated 
rearrangements (e.g. the VHL locus in von Hippel-Lindau disease patients), but is 
absent in the locus encompassing the DNA mismatch repair gene MLH1. These 
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Figure 2. Sequence a lignm ent o f tw o  A lu  repeats invo lved in tw o  d is tin c t EPCAM 
de le tions. A distal intragenic repeat (A/uSp, in green) and a proximal intergenic repeat 
(A/usSx, in blue) show high local sequence homology. The microhomology around the 
breakpoint in deletions 7 and 8 are marked by shaded boxes. Deletion 9 involves the same 
intragenic repeat, including a directly downstream located intergenic A/u repeat sequence 
(.FLAM-C), with a lack of local microhomology around the breakpoint. The position of the 
breakpoints and the insertion of a di-nucleotide sequence AG are indicated by triangles.
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Through detailed mapping and characterization of 3’ EPCAM gene deletions in 
Lynch syndrome families, we show that these deletions explain a considerable 
fraction (at least 1-3%) of all families with this syndrome, thus legitimating standard 
clinical testing. In total, we have identified and characterized 19 different EPCAM 
deletions in 45 Lynch syndrome families. These deletions turned out to be highly 
variable in size and location, but always encompassed the last two exons of the 
EPCAM gene, including its polyadenylation signal. In concordance with previous 
studies (Ligtenberg et al., 2009, Niessen et al., 2009, Nagasaka et al., 2010), all 
available tumor and normal colonic tissues showed hypermethylation of the MSH2 
gene promoter, thus confirming a direct correlation between these two aberrations. 
Detailed localization of the deletion breakpoints at the sequence level revealed 
A/u-mediated recombination as the major mechanism underlying the occurrence of 
EPCAM deletions.
The presence of a mono-allelic EPCAM deletion results in a highly efficient silencing 
of the MSH2 gene in target tissues such as colonic mucosa. This observation is in full 
agreement with the lifetime risk for colorectal cancer in these families, which appears 
to be similar to those observed in families with other MSH2 alterations (Kempers et 
al, 2010). This efficient MSH2 inactivation may be associated with one or more of the 
following structural characteristics of this locus: (i) the close vicinity of a neighboring 
gene (EPCAM) that is oriented towards MSH2, and (ii) the high level of expression of 
EPCAM in targeted tissues instilling MSH2 promoter methylation. Together with the 
relative high density of A/u repeat elements in this genomic region, which increases 
the chance of A/u-mediated recombination, these characteristics may explain the 
recurrent nature of variable EPCAM deletions in Lynch syndrome families.
Upon analysis of the genomic region encompassing the Lynch-associated DNA 
mismatch repair gene MLH1, we found that the above described characteristics do 
not apply to this locus. Consequently, we postulate that in the previously reported 
families with germline methylation of the MLH1 gene promoter, which in some 
families was found to be transmitted to next generations (Hitchins et al., 2007, Morak 
et al., 2008, Hesson et al., 2010), the mechanism causing methylation is very likely 
to be different.
Previous reports have already pointed at correlations between A/u repeat densities 
and the occurrence of genomic recombinations. For example, the VHL locus on 
3p25.3 has a local A/u element density which is comparable to that of the MSH2 
locus on 2p21, and a similarly high frequency and variety of A/u element-mediated 
deletions have been observed in von Hippel-Lindau disease families (Franke et al., 
2009, Nordstrom-O’Brien et al., 2010). Furthermore, gross chromosomal deletions in 
the MSH2 gene itself are also frequently observed and, in contrast to those found in 
the MLH1 gene, are all mediated by A/u element-mediated recombination (Wijnen et 
al., 1998, Li et al., 2006). The intragenic region of EPCAM contains 25 A/u elements, 
indicating that additional deletions may be encountered in the future. Eight of these 
elements are located upstream of exon 3 and were not involved in any of the deletions 
identified thus far, which may indicate that a minimum of three 5’ EPCAM exons are 




Despite the high variety of EPCAM deletions found, a relatively large proportion of 
the affected families shares one of at least seven distinct deletions that are likely of 
common ancestral origin, as has been demonstrated for the Dutch founder deletion 
(Ligtenberg et al., 2009). The relatively high frequency of EPCAM deletions among 
Lynch syndrome families in the Netherlands may very well be explained by the 
frequency of the founder deletion in this population.
Discrimination between putative molecular mechanisms involved in the formation 
of the EPCAM deletions requires a distinction between (i) meiotic recombination 
processes such as homology-dependent NAHR and homology-independent 
NHEJ, and (ii) mitotic processes including classical NHEJ and NHEJ mediated 
by microhomology (alt-NHEJ or MMEJ) and replication-based mechanisms 
such as microhomology-mediated break-induced repair (MMBIR) (Vissers et al.,
2009). The overlap in molecular fingerprints between these diverse molecular 
mechanisms makes it difficult to discern the mechanism underlying the formation 
of the deletions. Considering the high sequence homology between Alu repeats 
and the microhomology observed at the breakpoint junctions, however, non-allelic 
homologous recombination (NAHR) appears to be the most likely mechanism for 
most of the deletions.
Although the exact mechanism underlying the transcription-mediated epigenetic 
silencing of the MSH2 gene remains to be established, several studies have pointed 
at a correlation between transcription and DNA methylation. For example, maternal 
imprinting of the GNAS locus in mouse oocytes was recently shown to depend on 
transcription across the entire locus from the upstream NESP promoter (Chotalia 
et al., 2009), of which maternal micro-deletions cause pseudohypoparathyroidism 
type 1b in human (Bastepe et al., 2005). At non-imprinted loci, epigenetic silencing 
by antisense transcription has been reported for the alpha-globin gene promoter 
in alpha-thalassemia as well as for the p15 gene promoter in an in vitro system 
(Tufarelli et al., 2003, Yu et al., 2008). Finally, we have recently demonstrated that 
a constitutional partial duplication of the protein tyrosine phosphatase gene PTPRJ, 
a tumor suppressor gene associated with colorectal cancer susceptibility in the 
mouse (Ruivenkamp et al., 2002), induces hypermethylation of its own promoter by 
transcriptional read-through in a patient with colorectal cancer (Venkatachalam et 
al., 2010b). A possible explanation may include the formation of RNA-DNA duplexes 
within the promoter region that impinge the recruitment of the DNA methylation 
machinery resulting in epigenetic remodeling of the promoter, similar to what has 
been described for antisense non-coding RNAs (Hawkins et al., 2009). These 
observations by others and those reported by us indicate that DNA methylation 
instilled by transcriptional read-through across gene promoters may serve as a 
general mechanism governing health and disease.
In conclusion, we have demonstrated that 3’ EPCAM  deletions represent a common 
cause of Lynch syndrome. Based on this notion, the implementation of EPCAM 
deletion mapping in routine diagnostics on suspected Lynch syndrome families 
should be considered. Since all deletions appear to include at least the last two 
exons of the EPCAM gene, the inclusion of the corresponding EPCAM probes in 






Identification of CRC predisposing CNVs
The past decade has witnessed the elucidation of the genetic basis of several 
inherited cancer syndromes (Garber and Offit, 2005, Kuiper et al., 2010, McDermott 
et al., 2011). The identification of the genes involved in these syndromes has 
resulted in immediate benefits for genetic testing and counseling, pre-symptomatic 
screening and prevention in families, and has provided important insights into the 
molecular mechanisms underlying cancer susceptibility (Stoffel and Chittenden, 
2010). It was found that the activities of the identified genes target different tissues, 
and that their concomitant alterations lead to specific forms of cancer. For example, 
inherited mutations in the APC gene predispose to colorectal tumors, whereas 
inherited mutations in the VHL gene predispose to kidney tumors. Hereditary cancer 
syndromes are characterized by a relatively early age of onset, a frequent presence 
of bilateral tumors and a presence of multiple affected generations along the same 
family line. Furthermore, the genes involved are not only rate limiting for tumor 
initiation in these cancer syndromes, but tend to be mutated in sporadic cancers 
through somatic mutations as well.
Typical cancer families carry constitutional mutations in high-penetrant genetic 
factors, which were initially identified through linkage-based studies. In more recent 
years research into the genetic susceptibility to cancer has been dominated by a 
novel genetic approach, i.e., genome-wide association (GWA) analysis, which 
has resulted in the identification of multiple low-penetrant common variants (allele 
frequency >5%) associated with the occurrence of several cancer types, including 
colorectal cancer, breast cancer, prostate cancer, bladder cancer and lung cancer. 
Although the functional basis of these associations is not always apparent, it seems 
clear that the cumulative effect of multiple low-penetrant loci may eventually be 
employed for the prediction of an individual’s risk to develop cancer (Kingsmore et 
al., 2008; Janssens et al., 2008). In addition, it is reasonable to assume that at least 
part of the missing heritability may be explained by multiple rare variants occurring 
with frequencies of <1% and acting as independent dominant susceptibility factors, 
each conveying a moderate but significant increase in cancer risk (Figure 1). Due to 
their rare occurrence, however, neither classical linkage studies nor GWA analyses 
will allow the identification of these factors. Therefore, we have applied an alternative 
strategy to identify novel predisposing factors by screening individual patients for 
the presence of disease-causing DNA copy number variants (CNVs), i.e., deletions 
or duplications, using high-resolution genomic profiling. A major advantage of this 
approach is that it does not depend on large family or patient cohorts and/or dominant 
patterns of inheritance (chapter 1). CNVs frequently lead to disruption or deletion of 
genes and, therefore, they may have severe effects on cancer risk. In fact, CNVs 
affecting high penetrance cancer predisposing genes have already been reported, 
including the BRCA1 and BRCA2 genes, the VHL gene, the APC gene, and a variety 
of mismatch repair genes (Petrij-Bosch et al., 1997, Bunyan et al., 2004, Michils 
et al., 2005, Wijnen et al., 1998, Wagner et al., 2003, Plaschke et al., 2003). In 
addition, it was recently found that constitutional 3’ deletions of the EPCAM gene 
can lead to allele-specific epigenetic silencing of the downstream mismatch repair 
gene MSH2 (Ligtenberg et al., 2009), giving rise to a distinctive tumor susceptibility 
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Figure 1. Genetic contribution to colorectal cancer. Based on current knowledge, 
the susceptibility to develop colorectal cancer is influenced by many genetic 
factors that vary in penetrance (y-axis) and frequency (x-axis), indicated by the 
grey shaded region. Mutations in high penetrant genes, like APC and several mismatch 
repair (MMR) genes, occur at very low frequencies and have been found by positional 
cloning and linkage-based approaches. Several common risk factors have recently been 
identified by genome-wide association studies. They display a low relative risk and include 
for example rs16892766 (8q23.3) and rs6983267 (8q24.21). It has been hypothesized 
that a significant proportion of the 'missing heritability' is attributable to rare variants with 
intermediate penetrances, which have been difficult to identify by conventional gene 
discovery approaches. We anticipate that the candidate DNA copy number variations 
(CNVs) identified by our alternative strategy should be considered as rare variants with 
moderate penetrances. (Modified from: Manolio et al., 2009).
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CNVs leading to the disruption and/or silencing of critical genes could result in the 
identification of additional rare variants involved in moderate- to high-penetrance 
forms of cancer predisposition (Kuiper et al., 2010).
In order to test this hypothesis, we selected a discovery cohort of 41 unexplained 
colorectal cancer (CRC) patients based on stringent criteria with respect to age of 
onset and family history. As described in chapter 2, high-resolution genomic profiling 
of these patients has resulted in the identification of novel CNVs affecting the bone 
morphogenetic protein antagonist family gene GREM1, the breakpoint cluster 
region gene BCR, the protein tyrosine phosphatase gene PTPRJ, the cadherin gene 
CDH18 and the predicted protein-coding gene KIAA1797. In addition, two genomic 
deletions were encountered encompassing microRNA (miRNA) genes, namely miR- 
491 located within the KIAA1797 gene, and miR-646. The identification of unique 
gene-disrupting CNVs in 6 out of 41 (15%) unexplained early-onset and familial 
CRC cases indicates that germline CNVs may indeed play a significant role in CRC 
susceptibility and could fill in at least part of the so-called missing heritability gap 
(Kuiper et al., 2010).
Following the identification of these loci, several strategies were applied to collect 
evidence for a causal relationship to CRC susceptibility (Figure 2). First, the identified 
CNVs were compared with public and private databases to rule out the possibility 
that they represent harmless genomic copy number polymorphisms. Second, to test 
for recurrence we performed CNV and mutation screens in additional large cohorts 
of CRC index patients with an early age of onset and/or an overt family history. 
Third, we assessed the co-segregation of these CNVs with cancer incidence in 
family members. Fourth, to find out whether the identified candidate genes follow 
the classical tumor suppressor gene paradigm, we performed second-hit CNV and 
mutation analyses in the patient’s tumor material. Finally, all candidate genes were 
prioritized based on functional clues that could link them to CRC development.
Disease-causing versus benign CNVs
Because of the typical rare occurrence of CNVs in our studies, extensive control 
cohorts were required to establish a causal relationship with CRC development. 
Comprehensive copy number analyses in normal individuals over the last five years 
have yielded a detailed map of structural copy number variation, of which at least 
80% represents common CNVs with an allele frequency of >5% (Redon et al., 
2006, McCarroll et al., 2008, McMullan et al., 2009), which are thus unlikely to be 
associated with a high or moderate risk of disease. The majority of these CNVs is 
listed in the Toronto Database of Genomic Variants (http://projects.tcag.ca/variation) 
(lafrate et al., 2004), which contains >65,000 CNVs encompassing nearly 15,000 
loci (November, 2010), and provides an important source for the assessment of 
benign CNVs. A drawback of this database, however, is that many of the CNVs 
listed have not yet been validated. Furthermore, the listed CNVs have been detected 
using a variety of different platforms, which hampers the exact demarcation of the 
breakpoints. In addition, many CNVs exhibit population-specific allele frequencies, 
which may result in a bias in this database. Therefore, we have established an in­
house database, which contains platform-matched high-resolution genomic profiles
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Figure 2. Strategy to identify novel germline CNVs and to establish their causal 
relationship with CRC susceptibility. Colorectal cancer (CRC) patients were selected 
based on stringent criteria with respect to age of onset and family history. High-resolution 
genomic profiling was performed on germline DNA of these patients. All copy number 
variants (CNVs) present in public and private databases were excluded. The candidate CNVs 
were then validated using parallel techniques (e.g. MLPA, qPCR). To test for recurrence 
of mutations in the candidate genes, CNV and mutation screens were performed in large 
cohorts of CRC patients with an early age of onset and/or an overt family history. The co­
segregation of these CNVs with cancer incidence was assessed in family members. Also, 
second-hit CNV and mutation analyses in the patient's tumor material were performed. 
Finally, all candidate genes were prioritized based on their functional implications in CRC 
development.
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of locally collected healthy individuals. All profiling data of these individuals were 
normalized and analyzed following the same procedures as in our patient cohort. 
It turned out that the candidate CRC predisposing genes identified through this 
approach were not reported in any public and/or private sources of normal structural 
variation. In order to avoid the possibility of missing small CNVs in our candidate 
genes due to a low local coverage of probes (SNPs) on the microarrays used, 
we performed a PCR-based targeted locus-specific CNV analysis using multiplex 
ligation-dependent probe amplification (MLPA) on unaffected ethnicity-, gender- and 
age-matched controls for our candidate genes (Table 1). Also through this approach, 
no CNVs were detected. We conclude that the selective occurrence of candidate 
CNVs in CRC patients, but not in healthy controls, strongly supports their suspected 
role in CRC susceptibility.
Screening for recurrence
In order to further substantiate the role of the candidate CNVs in CRC susceptibility, 
we employed targeted locus-specific copy number and mutation analyses in an 
additional cohort of CRC patients with a familial history or an early age of onset. 
As of yet, two candidate genes, i.e., PTPRJ and KIAA1797/miR-491, were found 
to be recurrently affected in these patients (chapters 3 and 4). This recurrence 
underscores our notion that these genes may be associated with an increased CRC 
risk. It has been well-documented now that copy number variation in the normal 
population involves similarly affected regions in each individual (Korn et al., 2008, 
Barnes et al., 2008, Cooper et al., 2008, McCarroll et al., 2008). Our finding of distinct 
CNVs in the CRC index patients strongly argues against the possibility of these 
CNVs being harmless copy number polymorphisms. An additional mutation screen 
of the candidate genes PTPRJ and CDH18, and the two miRNA genes, miR-491 
and miR-646, in an independent cohort of CRC patients below the age of 40 (Table 
1) did not reveal any pathogenic nonsense or missense mutations. Although the 
CRC cohort on which we performed these analyses is as yet too small to draw any 
firm conclusions, it seems that at least for these four genetic factors point mutations 
do not serve as a frequent cause underlying CRC predisposition. The frequency in 
which our candidate genes are affected in CRC patients appears to be relatively 
low (<0.1%), similar to that of rare variants. In order to establish the true impact of 
the identified rare CNVs on cancer risk and/or spectrum, clearly more families with 
aberrations in these genes need to be collected (Kempers et al., 2011). Based on the 
rapid implementation of high-resolution genomic profiling methodologies in clinical 
diagnostics, it is anticipated that CNVs affecting candidate susceptibility genes will 
be detected at an increasing rate. Indeed, through this pipeline another duplication 
affecting PTPRJ in an independent patient with multiple polyps was encountered 
(unpublished data), thereby once more underscoring its significance. Consequently, 
we conclude that high resolution copy number profiling serves as a comprehensive 
approach to identify rare CNVs associated with cancer susceptibility.
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Table1: CNVs involved in CRC susceptibility
Gene Cyto-
band














PTPRJ 11p11 2/1497 0/96 0 0/1050 1
KIAA1797 9p21.3 3/1025 - 0 0/1880 0
miR-491 9p21.3 1/1025 0/96 0 0/1880 0
GREM1 15q13.3 1/289 - 0 - 0
BCR 22q11.23 1/289 - 0 - 0
CDH18 5p14.3 1/289 0/96 0 - 0
miR-646 20q13.33 1/289 0/96 0 - 0
1In-house database containing platform-matched high-resolution genomic profiles of 
locally collected healthy individuals. 2Locus specific screen was performed using MLPA on 
ethnicity-, gender-, and age-matched controls. 3Based on high-resolution genomic profile 
data (Affymetrix 250k SNP arrays) of patients with no or unknown cancer risk, obtained by 
array diagnostics in the department of Human Genetics Nijmegen.
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Co-segregation of CNVs in families
To further support the role of the identified rare CNVs in CRC susceptibility we 
examined its co-segregation with the disease in families. Due to the intrinsic selection 
criteria used and technical limitations such as lack of accessibility to DNA material 
and/or death due to cancer etc., these analyses turned out to be cumbersome. 
Nonetheless, we were able to establish co-segregation in some cases (chapters 
2-4). In most of the cases, however, the candidate CNVs were inherited from one 
of the non-affected parents, thus suggesting an incomplete penetrance and a 
concomitant moderate risk. It has been proposed that rare variants, though known to 
be enriched in familial cases, may not give rise to multiple affected family members 
since the penetrance of such variants is likely to be well below the 50% needed to 
give a familial concentration that resembles Mendelian segregation (Bodmer and 
Tomlinson, 2010). Hence, family-based studies are usually not conclusive for the 
interpretation of rare CNVs with moderate penetrances.
Knudson’s two-hit model
Classical tumor suppressor genes (TSGs) usually follow the so-called two-hit model 
originally put forward by Knudson (Knudson, 1971). This two-hit model has provided 
an experimental framework for the identification of TSGs via (i) the identification 
of a deleted chromosomal region in a tumor of a patient with a Mendelian cancer 
susceptibility syndrome and (ii) the identification of a gene in that region that is 
either present in a mutated form on the other allele, or homozygously deleted. Many 
Mendelian cancer predisposing genes such as APC, BRCA1, BRCA2 and VHL 
have been identified through this strategy and nicely follow this model (Tory et al., 
1989, Smith et al., 1992, Levy et al., 1994, Gudmundsson et al., 1995). In order 
to determine whether our newly identified candidate CNVs also follow Knudson’s 
two-hit model, we screened the index patient’s tumor material for the presence 
of second hit mutations and copy number changes (chapters 2-4). By doing so, 
we did not detect any pathogenic second hit mutations in the candidate CRC 
susceptibility genes PTPRJ, CDH18 and KIAA1797, suggesting that in these cases 
loss of function of the remaining allele is not required for tumor development. This 
scenario is known as haplo-insufficiency, where functional loss of one copy may 
confer tumor predisposition without requiring inactivation of the remaining allele for 
disease initiation. TP53, PTEN, DOK2 and FBXW7 represent a few examples of 
tumor suppressor genes (TSGs) exhibiting haplo-insufficiency (Kuiper et al., 2009, 
Berger and Pandolfi, 2011). It has already been suggested by others that identifying 
TSGs based only on Knudson’s two-hit model may be naïve, and that animal models 
and functional studies are vital to assess whether heterozygous losses as observed 
in human cancers are functionally relevant for tumor development (Berger and 
Pandolfi, 2011). Indeed, understanding the functional role of the identified candidate 
genes in CRC development may equally well be instrumental for associating them 
with an increased CRC risk.
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Functional implications of CRC risk
Many of the newly identified CRC susceptibility genes can be functionally linked to 
known CRC-associated cellular pathways and (early) CRC development (Figure 3). 
For example, the breakpoint cluster region gene BCR, affected by a partial duplication 
in one of our CRC index patients, was reported to be located within an instability- 
associated region that is affected in one-third of sporadic human CRCs (Bartos et al., 
2007). Furthermore, GREM1 has previously been identified as a putative Wnt target 
gene in the BMP pathway and SNPs in GREM1 were found to be strongly associated 
with an increased CRC risk (Jaeger et al., 2008, Lewis et al., 2010). In addition, 
GREM1 expression has been found to be up-regulated during the development of at 
least a subset of sporadic CRCs (Kosinski et al., 2007). Our finding of a duplication 
of the entire GREM1 gene suggests that over-expression of the protein in specific 
tissues such as colon may result in polyp-, adenoma- and carcinoma formation. The 
classical type-II cadherin CDH18 (formerly known as CDH14) is a trans-membrane 
protein that, like other cadherins, is involved in cell-cell adhesion. In addition, it 
has been found to be mutated in sporadic CRCs (Wood et al., 2007). Interestingly, 
CDH18 was originally isolated as an interactor of p-catenin and, as such, appears to 
be linked to the Wnt signaling pathway as well (Shibata et al., 1997). KIAA1797 was 
reported to interact with vinucelin VCL (de Hoog et al., 2004), a cytoskeletal protein 
associated with cell-cell and cell-matrix junctions involved in anchoring F-actin to the 
membrane (Hazan et al., 1997, Weiss et al., 1998). This latter association suggests 
that this hypothetical protein may have a role in cell-cell adhesion and, indirectly, in 
Wnt signaling as well.
The strongest functional support seems to be available for PTPRJ. Human PTPRJ 
was found to be deleted in several tumor types, including colon cancer (Ruivenkamp 
et al., 2002, Ruivenkamp et al., 2003, Iuliano et al., 2004). Deletion of PTPRJ was 
also frequently encountered in aberrant crypt foci, the earliest neoplastic lesions of 
the colon, suggesting a major role for this gene in early colon neoplasia (Luo et al., 
2006). The PTPRJ gene codes for the density-enhanced phosphatase DEP-1 (also 
designated CD148), which is up-regulated in confluent cell populations (Ostman et 
al., 1994). DEP-1 is a widely expressed candidate tumor suppressor involved in the 
control over cellular growth and transformation by antagonizing receptor tyrosine 
kinase activities (Keane et al., 1996, Trapasso et al., 2000, Kovalenko et al., 2000, 
Palka et al., 2003, Iuliano et al., 2003, Massa et al., 2004, Trapasso et al., 2004, 
Balavenkatraman et al., 2006). Additionally, recent loss-of-function analyses have 
revealed that DEP-1 may inhibit the motility and, presumably, invasion of tumor cells 
(Petermann et al., 2010). DEP-1 has been found to play an important role in the 
regulation of cell-cell adhesion through dephosphorylation of the cadherin-catenin 
complex at adherence junctions (Palka et al., 2003, Jandt et al., 2003, Grazia 
Lampugnani et al., 2003, Kellie et al., 2004, Lilien and Balsamo, 2005, Ostman et 
al., 2006). It has also been reported that deregulation of cadherin-catenin complexes 
may contribute to tumor development by affecting the adhesion of epithelial cells 
in the colon (Goss and Groden, 2000). Furthermore, it has been found that this 
deregulation may affect the Wnt signaling pathway by regulating the stability and 
sub-cellular localization of p-catenin (Fodde et al., 2001, Cavallaro et al., 2004). Also, 







Figure 3. Novel genes involved in colorectal cancer (CRC) susceptibility. Genome- 
wide copy number analysis in carefully selected unexplained cases at risk for hereditary 
CRC resulted in the identification of novel rare germline copy number variations (CNVs) 
involved in CRC predisposition. Based on existing literature, six genes identified by our 
approach were known to play a role in CRC susceptibility (light grey circle), (early) CRC 
development (white circle), or could be functionally linked to known CRC-associated 
pathways (dark grey circle).
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tissues mediated by cell surface adhesion, cell-cell recognition and regulation of the 
actin cytoskeleton (Tepass et al., 2000). p-catenin not only regulates Wnt signaling 
but has also been implicated in the rearrangement of mitotic spindles (Cabello et al., 
2010). Classical cadherins affect tissue organization by acting as cues that orient the 
mitotic spindle during symmetric cell divisions in mammalian epithelia (den Elzen et 
al., 2009). Thus, the cell adherens junction components, including E-cadherin and 
p-catenin, which regulate Wnt signaling, are also responsible for spindle orientation 
in mitosis (Tepass 2002, Inaba et al., 2010, Cabello et al., 2010). Interestingly, it has 
been proposed that another CRC predisposing gene, APC, acts as a multifunctional 
tumor suppressor that, besides suppressing canonical Wnt signaling, also promotes 
tumorigenesis through loss of cell adhesion (Birchmeier et al., 1995, Bienz and 
Hamada, 2004, Aoki and Taketo, 2007). Furthermore, a mutation in Apc in mouse 
intestinal epithelial cells was found to decrease the level of E-cadherin at the cell 
membrane (Carothers et al., 2001). Correspondingly, human APC has been found to 
regulate microtubule networks and to play a role in microtubule-mediated processes 
such as cell migration and mitotic spindle formation (Fodde et al., 2001, Nathke 
et al., 2006). Together, this information suggests that three of our newly identified 
candidate CRC susceptibility genes, PTPRJ, CDH18 and KIAA1797, may play a role 
in CRC related pathways such as Wnt signaling, cell-cell adhesion and mitotic spindle 
orientation. Our strategy has shown to be successful not only in the identification of 
novel CRC susceptibility genes, but also in exposing important functional pathways 
that may play a crucial role in CRC susceptibility. Thus, grouping of variants based 
on gene function in single biochemical pathways (Bodmer and Tomlinson, 2010) 
may be considered as a strategy to search for novel rare CRC susceptibility variants. 
Mouse Ptprj was previously identified as the target gene in a colon cancer 
susceptibility locus Scc1 (Ruivenkamp et al., 2002). Despite all above mentioned 
observations, however, the role of DEP-1 in CRC predisposition still appears to be 
complex. Homozygous Ptprj knock-out mice develop normally and show no signs 
of tissue abnormalities and/or increased tumor incidence (Trapasso et al., 2006), 
and a mutation scan of the entire protein tyrosine phosphatase gene family in 18 
colorectal tumors failed to reveal any pathogenic mutations (Wang et al., 2004). On 
the other hand, transgenic mice, in which the intracellular catalytic domain of DEP-1 
was replaced by enhanced green fluorescent protein, died at mid-gestation because 
of defects in vascular development, suggesting that the extracellular DEP-1 domain 
in these mice acts as a functional ligand that interferes with normal vascularization 
(Takahashi et al., 2003). In spite of its complexity, however, the mouse studies 
provide compelling evidence for a role of Ptprj in CRC susceptibility, either directly or 
as a trans-acting modifier (see below).
MiRNAs and CRC susceptibility
Non-coding RNAs such as miRNAs have been found to be up- or down-regulated 
in various tumor types (Volinia et al., 2006), and examples of germline mutations 
and SNPs in miRNAs in cancer predisposition have been reported as well (Calin 
et al., 2005, Jazdzewski et al., 2008). We identified deletions in at least two miRNA 
genes, i.e., miR-491 and miR-646. This observation may be significant as well since
110
deletions in miRNA genes may affect the expression of specific target genes that act 
in CRC-associated pathways, thus leading to CRC development. In particular, miR- 
491 may be considered as a CRC predisposing factor since it has been shown that 
this miRNA can induce apoptosis by targeting Bcl-X(L) in CRC cells (Nakano et al., 
2010). In the human CRC cell line DLD-1, miR-491 expression was found to markedly 
inhibit cell viability in vitro and its over-expression was found to inhibit tumor growth 
in vivo (Nakano et al., 2010). In addition, over-expression of miR-491 sensitizes 
HepG2 cells for tumor necrosis factor-a (TNF-a)-induced apoptosis (Yoon et al.,
2010). It has also been demonstrated that miR-491-5p expression can be induced 
by TGF-p1 through the MEK/p38MAPK pathway, a well-known pathway involved in 
tumor development (Zhou et al., 2010). Moreover, it is remarkable to note that two of 
the five candidate loci that we identified included miRNA genes. At present, there are 
about 1,000 annotated miRNAs genes reported in the miRNA database (miRBase). 
Based on our in-house CNV control database we estimate that ~100 of these genes 
are affected by normal copy number variation (chapter 5). The role of germline CNVs 
affecting miRNA genes in cancer predisposition has, as yet, poorly been studied. In 
order to further explore the role of such CNVs in CRC susceptibility, we performed 
targeted copy number profiling of annotated miRNA genes using a custom-designed 
tiling oligonucleotide microarray in a carefully selected cohort of CRC patients below 
the age of 40 years. To the best of our knowledge this array is the first of its kind with 
an ultra-high resolution, thus allowing the detection of small sized CNVs specifically 
affecting miRNAs. Indeed, using this microarray we were able to detect such CNVs. 
Unfortunately, however, it turned out that these CNVs were as yet difficult to validate 
by independent means, possibly due to the complex architecture of the CNVs or the 
occurrence of repetitive sequences in the genomic regions involved. The availability 
of next generation sequencing approaches may circumvent these problems and 
enable the detection of CNVs and/or mutations affecting miRNA genes in a more 
comprehensive manner. Together, our findings suggest that miRNA genes may be 
more commonly affected by constitutional CNVs than previously thought and, as 
such, may play a significant role in CRC susceptibility.
Moderate risks and modifier genes
Modifier genes are defined as genes that affect the expression of other genes. 
Genetic modifiers can affect penetrance, dominance, expressivity and pleiotropy 
(Nadeau et al., 2001). A classical example of a modifier gene comes from the APCmin/+ 
mouse model, a murine counterpart of human FAP (chapter 1; Moser et al., 1990). 
These mice exhibit a wide phenotypic variation, for example in the number of polyps, 
depending on the genetic background. By linkage analysis, a modifier gene originally 
called Mom1 for ‘modifier of Min’ in the APCmin/+ mouse model was mapped to the 
distal part of chromosome 4 (Dietrich et al., 1993). This modifier was able to explain 
50% of the genetic variance in polyp number, indicating that yet another modifier 
with a semi-dominant effect on polyp number probably exists (Nadeau, 2001). Such 
a scenario may very well apply to some of our newly identified candidate genes as 
well, including the PTPRJ gene. In fact, mouse Ptprj has been suggested to function 
as a genetic modifier affecting penetrance (Ruivenkamp et al., 2002, Lesueur et
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al., 2005). Also, in colorectal adenomas LOH of PTPRJ is found to occur as an 
early event followed by the loss of chromosome 18q12-21, which includes genes 
like SMAD4 and SMAD2 (Ruivenkamp et al., 2003). Patients harboring a duplication 
in the PTPRJ gene seem to exhibit varying phenotypes ranging from juvenile polyps 
to carcinomas. Since there is ample evidence that independent genetic factors can 
modify the cancer risks in mutation carriers in Mendelian cancer syndromes (Antoniou 
and Chenevix-Trench, 2010), it is conceivable that the newly identified candidate 
CNVs may equally well act as genetic factors that modify CRC risk in carriers of 
these mutations. So far, candidate gene studies have not been very successful in 
identifying such modifiers and most attempts have been underpowered. Only GWA 
studies have been successful in the identification of variants that may modify cancer 
risks (Antoniou and Chenevix-Trench, 2010). From our results we conclude that, as 
an adjunct to GWA studies, high-resolution copy number profiling can be employed 
as an approach to identify genetic modifiers in cancer syndromes.
Epigenetic mechanisms
Copy number variants can also affect cancer predisposition through epigenetic 
mechanisms. Our group has demonstrated that 3’ end deletions of the EPCAM gene 
may predispose to CRC and, thereby, represent a novel cause of Lynch syndrome 
(Ligtenberg et al., 2009, Kempers et al., 2011; chapter 6). Interestingly, the 
underlying mechanism was found to involve a failure in transcriptional termination 
of EPCAM , resulting in the generation of fusion transcripts with the downstream 
MSH2 gene. This transcriptional read-through turned out to result in methylation 
of the MSH2 promoter in tissues expressing high levels of EPCAM (Ligtenberg et 
al., 2009). We have identified and characterized 19 different EPCAM deletions in 
45 lynch syndrome cases from multiple geographical origins (chapter 6). These 
deletions, though variable in size and location, always encompassed the last two 
exons of the EPCAM gene, which includes its polyadenylation signal. By detailed 
breakpoint mapping of these deletions we concluded that these 3’ end EPCAM 
deletions most likely originate from A/u-mediated recombination events. In addition, 
it was found that carriers of EPCAM deletions that lead to tissue-specific inactivation 
of the MSH2 gene have a high risk to develop colorectal cancer, which is similar to 
that noted in carriers of MLH1 or MSH2 mismatch-repair gene mutations. However, 
Lynch syndrome patients with deletions extending close to the MSH2 gene promoter 
appeared to have an increased risk of endometrial cancer, similar to that observed 
in Lynch syndrome (Kempers et al., 2011). The identification and characterization of 
EPCAM deletions by copy number analysis has provided a basis for an optimized 
protocol for the recognition and targeted prevention of cancer in EPCAM deletion 
carriers. Hence, implementation of EPCAM deletion mapping in routine diagnostics 
should be seriously considered for suspected Lynch syndrome families (chapter 
6). Specifically, clinical screening could be focused exclusively on CRC. Therefore, 
women could be prevented from surveillance and prophylactic hysterectomy. This 
work once again shows that different anomalies within one gene may have diverse 
effects on disease manifestation. Despite the fact that the exact mechanism(s) 
underlying transcription-mediated epigenetic silencing of the MSH2 gene still
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remains to be established, there are other examples in the literature describing 
similar phenomena. For example, aberrant constitutional hyper-methylation and 
silencing of the a-globin (HBA2) gene has been reported in an individual with 
a-thalassemia. In this case a 3’ truncating deletion of the downstream LUC7L gene 
caused antisense transcriptional read-through and hypermethylation of the in cis 
HBA2 gene promoter and a concomitant silencing of the gene, leaving the gene 
itself intact (Tufarelli et al., 2003). Similarly, Yu et al. (2008) found that antisense p15 
RNA expression can induce epigenetic chromatin changes resulting in cis hyper­
methylation of the p15 gene promoter and silencing of the gene. It has also been 
shown that maternal imprinting of the GNAS locus in mouse oocytes depends on 
transcription across the entire locus from the upstream NESP promoter (Chotalia et 
al., 2009), of which maternal microdeletions cause pseudohypoparathyroidism type 
1b in human (Bastepe et al., 2005), clearly pointing towards a correlation between 
transcription and DNA methylation. One possible explanation of the identified 
mechanism could be RNA-DNA duplex formation within the promoter region that 
might interrupt recruitment of the DNA methylation machinery resulting in epigenetic 
remodelling of the promoter (Hawkins et al., 2009).
The constitutional DNA duplication affecting the protein tyrosine phosphatase PTPRJ 
gene in one of our familial cases of early-onset CRC showed a head-to-tail in tandem 
configuration. This configuration again resulted in transcriptional read-through and 
concomitant allele-specific silencing of (in this case) the wild type PTPRJ locus 
by in cis promoter hyper-methylation (chapter 3). Based on these observations, it 
is tempting to speculate that a variety of genomic alterations, including deletions, 
duplications, inversions and translocations, which may induce aberrant promoter 
methylation through transcriptional read-through, still awaits discovery (Figure 
4) (Kuiper et al., 2010). Since most tumor suppressor genes associated with 
Mendelian cancer syndromes contain CpG island promoters, which can be affected 
by transcriptional read-through, targeted analysis of their neighboring genes should 
be considered. Furthermore, high-throughput copy number analysis of unexplained 
high-risk families may reveal additional tumor suppressor genes that are similarly 
targeted by transcriptional read-through mediated silencing.
From bench to clinic
The identified candidate genes may, next to their potential role in CRC development, 
also be of clinical relevance, especially for CRC families with individuals carrying 
aberrations in these genes. Predictive clinical genetic testing is currently available 
for various Mendelian cancer syndromes, including FAP (APC, MUTYH) and Lynch 
syndrome (MSH2, EPCAM, MLH1, MSH6, PMS2), and patients carrying mutations in 
either one of these high penetrance genes may immediately be subjected to intensive 
surveillance. However, genetic testing and counseling still remains a challenge in 
cancer families with an obvious strong suspicion for genetic predisposition, but without 
overt pathogenic mutations in any of the known high penetrance genes. Hence, for 
clinical practice, the implementation of additional susceptibility variants, including 
those with lower penetrances, will be of paramount importance. Ideally, a cumulative 
risk model might be applied in which the presence of multiple susceptibility loci is
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Figure 4. Epigenetic silencing induced by copy number variants. Gene silencing 
(indicated by orange ovals) induced by sense or antisense read-through of truncated 
transcriptional units into a CpG island promoter. Transcriptional read-through can occur 
by (a) deletion of the 3'-region of a gene or (b) duplication or (c) translocation of an active 
promoter element into another genomic region. Germline epigenetic silencing might 
be mosaic due to tissue-specific activity of the promoter. Note that in case of a tandem 
duplication, gene silencing can be induced by a partially duplicated (3' deleted) version of 
the gene itself (as indicated in b). (from: Kuiper et al., 2010).
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included, resulting in a personalized risk prediction. Unfortunately, the various low- 
penetrant CRC susceptibility loci that have been identified via GWA studies in the 
last five years have an as yet limited clinical relevance, since they each contribute 
little to an individual’s risk. In contrast, moderate risk factors and modifiers such as 
those identified in our study might very well be used in this manner. These candidate 
CNVs were detected in CRC families stringently selected for early age of onset or 
overt family history, and were all found to result in loss or disruption of the affected 
candidate gene. However, considering the incomplete penetrance in most of these 
families, we expect that other as yet unidentified genetic (or other) factors might also 
add to the increase in relative risk. Hence, an ideal strategy for better understanding 
CRC predisposition and development would be to integrate information from SNP, 
CNV and the rapidly growing body of whole genome sequencing data. This wealth 
of information will, without any doubt, augment novel genetic testing strategies 
and genetic counseling. In addition, even with a modest genotype-phenotype 
association, the identified candidate genes can offer considerable new translational 
prospects through the identification of novel modifiable cellular pathways (McCarthy 
et al., 2008). Indeed, our approach has been successful in the detection of pathways 
that might play an important role in CRC development. This provides new avenues 
for the identification of therapeutic targets within these pathways, leading to novel 
therapeutic strategies for treatment and prevention.
We and others have shown that copy number variation analysis is instrumental for 
the identification of novel moderate- to low-penetrant CRC predisposing genes. It 
has also become clear that rare CNVs can target genes that act in cancer-related 
pathways, thereby resulting in a high cancer risk. Since these CNVs can easily be 
interrogated in genome-wide screens, genomic profiling strategies can efficiently be 
deployed in the search for novel cancer-predisposing genes. In the near future, the 
detection of new copy number variants, including micro-deletions and duplications, 
by novel strategies such as high throughput paired-end mapping using large scale 
genomic (re-)sequencing (Korbel et al., 2007) is anticipated to further revolutionize 
this field of research. With these technical possibilities within reach, also additional 
new concepts of gene inactivation may be uncovered, as has e.g. been shown for 
the deletion of the 3’end of EPCAM that leads to Lynch syndrome through epigenetic 
silencing of the downstream MSH2 gene. The identification of a head-to-tail in 
tandem duplication resulting in a transcriptional read-through and concomitant allele- 
specific epigenetic silencing of the wild type PTPRJ locus as reported in this thesis 
indicates that gene silencing by transcriptional read-through of a neighboring gene 
may represent a general mutational mechanism. We conclude that the application 
of new comprehensive genomic strategies will lead to the identification of novel 
CRC predisposing genes and mechanisms in an increasingly rapid pace. This, in 
turn, is expected to provide further insight into the etiology of CRC and to open up 
new avenues for improved diagnosis, prognosis and (personalized) therapy of both 
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Darmkanker is wat betreft incidentie en sterftecijfer de op twee na meest voorkomende 
kankersoort in de westerse wereld. Tweelingstudies hebben aangegeven dat in 20 
tot 30% van de gevallen de aanleg voor het ontwikkelen van darmkanker erfelijk kan 
zijn. Tot op heden vormen hoog penetrante kiembaan mutaties een verklaring voor 
slechts 5% van deze erfelijke aanleg. Aangenomen wordt dat de overige, nog niet 
opgehelderde, genetische factoren DNA varianten zijn elk met een gemiddelde tot 
lage penetrantie. In een poging om deze varianten te identificeren hebben wij een 
nieuwe strategie toegepast waarbij individuele patiënten werden gescreend op het 
voorkomen van kiembaan variaties (‘copy number variants’, CNVs), zoals deleties 
en duplicaties, met behulp van hoge resolutie DNA profilering. Een belangrijk 
voordeel van deze aanpak is dat deze niet afhankelijk is van de beschikbaarheid 
van grote aangedane families, uitgebreide patiënt cohorten en/of de aanwezigheid 
van dominante overervingpatronen (Hoofdstuk 1).
Hoge resolutie DNA profilering werd uitgevoerd in een patiënten cohort dat op basis 
van strikte criteria werd geselecteerd, waaronder een relatief jonge leeftijd waarop 
de kanker zich manifesteerde en/of de aanwezigheid van een duidelijke familie 
geschiedenis (Hoofdstuk 2). Op deze manier konden inderdaad unieke CNVs 
worden gedetecteerd die nieuwe kandidaat genen bleken te bevatten, zoals GREM1, 
BCR, PTPRJ, CDH18 en KIAA1797. Daarnaast werden twee deleties gevonden met 
daarin de microRNA kandidaat genen miR-491 en miR-646. De detectie van deze 
unieke CNVs in 6 van de 41 (15%) geselecteerde darmkanker patiënten geeft aan 
dat kiembaan CNVs inderdaad een belangrijke rol kunnen spelen in de erfelijke 
aanleg voor darmkanker.
Een van de nieuwe kandidaat genen, PTPRJ, is in detail beschreven in Hoofdstuk 
3. In dit hoofdstuk wordt ook een epigenetisch mechanisme beschreven dat leidt tot 
uitschakeling van dit gen. Op basis hiervan suggereren wij dat CNV-gerelateerde 
epimutaties mogelijk vaker een oorzaak vormen voor de erfelijke aanleg van 
darmkanker. Tevens konden wij een mogelijke rol van de KIAA1797/miR-491 regio 
in de erfelijke aanleg voor darmkanker onderbouwen via het doelgericht screenen 
van een uitgebreid cohort darmkanker patiënten: CNVs in deze regio werden 
herhaaldelijke teruggevonden in deze patiënten, maar niet in een controle cohort 
van meer dan 3,400 niet aangedane individuen (Hoofdstuk 4).
Op basis van onze bevinding in Hoofdstuk 2 dat CNVs die miRNA genen bevatten 
de aanleg zouden kunnen verklaren voor erfelijke darmkanker, hebben wij getoetst 
of en hoe vaak miRNA genen zijn betrokken bij CNVs in darmkanker patiënten in 
vergelijking met CNVs in niet aangedane individuen (Hoofdstuk 5). Onze voorlopige 
resultaten laten zien dat, enerzijds, frequent voorkomende CNVs in niet aangedane 
individuen miRNA genen kunnen bevatten (polymorfismen) en dat, anderzijds, 
zeldzame CNVs miRNA genen kunnen bevatten die mogelijk betrokken zijn bij de 
erfelijke aanleg voor darmkanker.
Via het exact lokaliseren van 3’ EPCAM  gen deleties in patiënten met Lynch 
syndroom hebben wij in Hoofdstuk 6 laten zien dat deze deleties een aanzienlijk 
deel van de aangedane families kunnen verklaren, en dus een veel voorkomende 
oorzaak kunnen vormen voor Lynch syndroom. Op basis hiervan concluderen wij dat 
de implementatie van EPCAM deletie detectie in de routine diagnostiek van Lynch 
syndroom serieus moet worden overwogen.
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Samengevat laten onze resultaten zien dat hoge resolutie DNA profilering in strikt 
geselecteerde, onverklaarde patiënten met een risico op erfelijke darmkanker, kan 




Colorectal cancer (CRC) is the second most common cause of cancer-related death 
in the Western world in terms of both incidence and mortality rate. Twin studies have 
suggested that about 20 to 30% of the CRC cases may be ascribed to a genetic 
susceptibility. Nevertheless, high-penetrance germline mutations account for less 
than 5% of the hereditary cases. It is assumed that the majority of the remaining 
genetic factors involve moderate- to low-penetrance genomic variants. In order to 
identify novel predisposing genetic factors we have applied a novel comprehensive 
strategy that involves the screening of individual patients for the presence of germline 
copy number variants (CNVs), i.e., deletions or duplications, using high-resolution 
genomic profiling. A major advantage of this approach is that it does not depend on 
large family or patient cohorts and/or dominant patterns of inheritance (Chapter 1). 
High-resolution genomic profiling was performed on a discovery cohort of unexplained 
CRC patients based on stringent criteria with respect to age of onset and family history 
(Chapter 2). By doing so, novel CNVs affecting the bone morphogenetic protein 
antagonist family gene GREM1, the breakpoint cluster region gene BCR, the protein 
tyrosine phosphatase gene PTPRJ, the cadherin gene CDH18 and the predicted 
protein coding gene KIAA1797 were identified. In addition, two genomic deletions 
were encountered encompassing non-protein coding microRNAs (miRNAs), i.e., 
miR-491 located within the KIAA1797 gene, and miR-646. The identification of 
unique gene-disrupting CNVs in 6 out of 41 (15%) unexplained early-onset and/or 
familial CRC cases indicates that germline CNVs may indeed play a significant role 
in CRC susceptibility and could fill in at least part of the so-called missing heritability 
gap.
The identification of one of these novel candidate CRC predisposing genes, PTPRJ, 
is described in further detail in Chapter 3. In addition, we report in this chapter the 
underlying epigenetic mechanism that leads to gene silencing, suggesting that CNV- 
based epimutations may serve as a more general mechanism in CRC predisposition. 
We have also established the relevance of the KIAA1797/miR-491 locus in CRC 
predisposition through targeted DNA copy number screening in a large cohort of 
familial and/or early-onset CRC patients. By doing so, we found KIAA1797/miR-491 
to be recurrently affected in these patients, but not in >3,400 non-affected individuals, 
which strongly supports a role for this locus in CRC susceptibility (Chapter 4). 
Based on our finding in Chapter 2 that CNVs affecting miRNAs may result in 
moderate- to high-penetrance forms of disease predisposition, including CRC, we 
assessed the occurrence and frequency of miRNA CNVs in a cohort of early-onset 
familial CRC patients and a matched cohort of unaffected controls (Chapter 5). 
From our results we were able to conclude that common CNVs (polymorphisms) 
may include miRNAs and that rare CNVs encompassing miRNAs may affect CRC 
susceptibility.
Through detailed mapping and characterization of 3’ EPCAM  gene deletions in Lynch 
syndrome patients, we were able to show that these deletions explain a considerable 
fraction of the affected families and thus represent a common cause of Lynch 
syndrome (Chapter 6). We conclude that, based on this notion, the implementation 
of EPCAM deletion mapping in routine diagnostics on suspected Lynch syndrome 
families should be considered.
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Taken together, our results illustrate that genome-wide copy number analyses in 
carefully selected unexplained cases at risk for hereditary CRC may serve as a novel 
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C hapter 1, F igure 1. Genetic model fo r co lo recta l tum origenes is . Colorectal carcinomas 
arise as result of a series of genetic alterations involving a handful of oncogenes and 
tumor suppressor genes. The earliest stages of the adenoma-carcinoma sequence is the 
aberrant crypt focus (ACF), which is associated with loss of the APC tumor suppressor 
gene function. Intermediate/late adenomas and early carcinomas are associated with the 
acquisition of mutations in the KRAS oncogene, followed by losses of or mutations in the 
SMAD4 and TP53 tumor suppressor genes. (Adapted from: Fodde et al., 2001).
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Chapter 1, Figure 2. Epigenetic marks, including DNA cytosine méthylation (Me) 
and covalent histone acetylation (Ac) or methylation (Me), that affect transcription.
(Adapted from: Jones et al., 2008).
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Colour Figures
Chapter 1, Figure 3. Colorectal cancer (CRC) incidence. CRCs can be divided into 
sporadic, familial and hereditary cases. In total, 35% of the CRCs are assumed to result 
from a genetic defect but, as yet, only ~5% of them has been associated with a high­
penetrant dominant or recessive inherited syndrome, such as Lynch syndrome. In 20-30% 
of the familial and de novo early-onset CRC patients (usually classified as sporadic; black 
dots), the genetic defect remains to be resolved. This sub-group has been the focus of our 
study to identify novel CRC susceptibility genes. (Adapted from: Lynch et al., 2004).
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C hapter 2, F igure 1. Deletion w ith in  the  type-II cadherin  gene CDH18. (A) Pedigree 
showing two brothers (II:1 and II:3) with colorectal cancer, both at 49 years of age (CRC49; 
closed symbols). Patient II:1 is index patient #39 (arrow). Deceased persons are indicated 
by a diagonal line. (B) CNAG plot of the short arm of chromosome 5 in patient #39 and 
structural organization of the CDH18 gene, showing an intragenic deletion of exon 2 which 
disrupts the open reading frame of the gene. (C) Validation of the genomic deletion by 
MLPA in both germline (blue line) and tumor (green line) DNA of patient II:1, as well as in 
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Chapter 2, Figure 2. Lesions identified in four familial and/or early-onset CRC patients.
Left panels depict whole chromosome genomic plots showing the candidate CNVs (indicated 
by arrow heads) affecting SCG5 and GREM1 (A), MFHAS1 (B), BCR (C), KIAA1797/miR- 
491 (D) and AK309218/miR-646 (E). Log2 test-over-reference ratios of hybridization signals 
of individual SNPs are indicated by red dots. Blue lines represent a ten SNP moving average. 
Right panels show the validation of each of the identified CNVs by MLPA (A,C,D,E; purple 
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Chapter 3, Figure 1. An inherited duplication affecting the protein tyrosine phosphatase gene PTPRJ. (A) Pedigree showing the 
index patient (lll:4  arrow) and her grandm other (l:2), both w ith colorecta l cancer at 36 and 65 years of age, respectively (closed symbols). 
Deceased persons are indicated by a diagonal line. (B) Copy num ber profile o fth e  short arm  o f chrom osom e 11 and structural organization 
o f the PTPRJ gene, showing the position o fth e  duplicated region affecting the 5 ’ part o fth e  gene. (C) Validation and segregation analyses 
by MLPA showing tha t the constitutional duplication in the index patient (green line) is also present in its tum or DNA (blue line) and the 
germ line DNA o fth e  unaffected fa ther (11:1 purple line; currently 71 years old). Germ line DNA from  the m other ( 11:2 pink line) does not show 
the duplication. B lack lines represent normal control DNAs. (D) Sequence analysis o fth e  cloned -1 8 0  bp PCR fragm ent revealing the exact 
breakpoints and the tandem  duplication in a head-to-tail orientation.
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Chapter 3, Figure 2. Germline epimutation of the protein tyrosine phosphatase PTPRJ 
gene induced by a constitutional micro-duplication. (A) Schematic representation of 
the head-to-tail in tandem micro-duplication encompassing exons 1-11 of the PTPRJ gene. 
Transcription of the duplicated segment reads through into exon 2 of the downstream 
intact copy of the gene, thereby inducing hypermethylation and subsequent silencing of 
its CpG island (CGI) promoter. (B) RT-PCR analysis using primers in exon 11 (P11F) and 
exon 3 (P3R) of the PTPRJ gene, revealing an aberrant fusion transcript (see also 2C) in 
lymphoblastoid cells (LC), normal colon mucosa (NC) and tumor (Tu) of the index patient 
(III:4) as well as in lymphoblastoid cells of her father (II:1), but not in an unaffected control 
(C) lymphoblastoid cells (LC). An exon 13 to exon 14 (P13F-P14R) RT-PCR product was 
used as input control. (C) Sequence analysis of the P11F-P3R RT-PCR fragment derived 
from patient III:4 showing the aberrant transcript fusion between exon 11 and exon 2. (D) 
Sequence of PTPRJ exon 13 using lymphoblastoid cell-derived genomic DNA showing a 
coding SNP rs4752904 (middle) which is heterozygous in the patient (III:4) and homozygous 
in the father (II:1), both carriers of the duplication. Sequencing of the expressed PTPRJ 
transcripts revealed that only the wild-type C-allele was expressed, whereas an unrelated 
heterozygous control sample showed normal bi-allelic expression. (E) and (F) Relative 
levels of methylation in lymphoblastoid cells (LC), normal colon mucosa (NC) and tumor 
(Tu) of the index patient (in duplo) and in nine unrelated controls as determined by bisulfite 
sequencing of an amplified region within the CpG island of the PTPRJ promoter. For each 
amplicon, 20-25 independent clones were sequenced. Depicted are the percentages of 
clones showing <30% methylation (white bars), 30-60% methylation (grey bars), and >60% 
methylation (black bars).
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Chapter 4, Figure 1. Recurrent deletions in KIAA1797/miR-491 locus (A) Structural 
organization of the KIAA1797/miR-491 locus, showing intragenic KIAA1797/miR-491 
deletions in patient #1 (red bar), patient #2 (blue bar) and patient #3 (green bar). (B) 
Validation of the genomic deletion by MLPA in germline DNA of patient #1 (red line) and 
identification of genomic KIAA1797/miR-491 lesions by MLPA in the germline in patient 
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Chapter 5, Figure 2: Array CGH profiling of germline DNA of a CRC patient using 
a custom-designed miRNA microarray and its validation. (A) Copy number plot of a 
chromosomal segment depicting the targeted coverage of 17 miRNAs within this region, 
of which miR-646 shows amplification (arrow). (B) Zoom-in of the region around miR-646, 
showing amplification (300 bp region) within an intron of a hypothetical gene. (C) Validation 
of the 300 bp genomic amplification by MLPA in DNA of the CRC patient (grey line). The 
black coloured lines represent normal control DNAs.
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C hapter 6, F igure 1. EPCAM de le tions in Lynch syndrom e patients. (A): Schematic 
outline of the genomic region around EPCAM and MSH2, showing 19 different deletions 
(grey bars) identified in 45 families. All deletions include at least exons 8 and 9 of EPCAM. 
Deletions identified in multiple (apparently) unrelated families are indicated in dark grey. 
Positions of the MLPA probes used for deletion mapping are indicated by triangles. All 
intragenic (B) and intergenic (C) breakpoints are located in Alu repeats (referred to as 
SINEs: short interspersed nuclear elements, red bars), of which eight are involved in 
several different deletions (indicated by arrows and numbers of the deletion). Arrowheads 
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C hapter 6, F igure 2. Sequence a lignm ent o f tw o  A lu  repeats invo lved in tw o  d is tin c t 
EPCAM de le tions. A distal intragenic repeat (AluSp, in green) and a proximal intergenic 
repeat (AlusSx, in blue) show high local sequence homology. The microhomology around 
the breakpoint in deletions 7 and 8 are marked by shaded boxes. Deletion 9 involves 
the same intragenic repeat, including a directly downstream located intergenic Alu repeat 
sequence (FLAM-C), with a lack of local microhomology around the breakpoint. The 
position of the breakpoints and the insertion of a di-nucleotide sequence AG are indicated 
by triangles.
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Chapter 7, Figure 4. Epigenetic silencing induced by copy number variants. Gene 
silencing (indicated by orange ovals) induced by sense or antisense read-through of 
truncated transcriptional units into a CpG island promoter. Transcriptional read-through can 
occur by (a) deletion of the 3'-region of a gene or (b) duplication or (c) translocation of an 
active promoter element into another genomic region. Germline epigenetic silencing might 
be mosaic due to tissue-specific activity of the promoter. Note that in case of a tandem 
duplication, gene silencing can be induced by a partially duplicated (3' deleted) version of 
the gene itself (as indicated in b). (from: Kuiper et al., 2010).
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